

# ProtecT study

**Prostate testing for cancer and Treatment**

**Protocol v 4.0  
November 17<sup>th</sup>, 2017**

**ISRCTN20141297  
HTA No 96/20/99**

**Principal Investigators:**

**FC Hamdy<sup>1</sup>**

**JL Donovan<sup>2</sup>**

**DE Neal<sup>3</sup>**

**Trial Co-ordinator:**

**JA Lane<sup>4</sup>**

<sup>1</sup>University of Oxford, Nuffield Dept of Surgery, Oxford OX3 9DU

<sup>2</sup>Department of Social Medicine, University of Bristol, Bristol BS8 2PR Tel: 0117 9287214

<sup>3</sup>University of Oxford, Nuffield Dept of Surgery, Oxford OX3 9DU Tel: 01865 617126

<sup>4</sup>Department of Social Medicine, University of Bristol, Bristol BS8 2PR Tel: 0117 9287335

**Study Title:** The ProtecT trial – Evaluating the effectiveness of treatments for localised prostate cancer

**Internal Reference Number / Short title:** ProtecT trial

**Ethics Ref:** MREC 01/4/025

**Date and Version No:** 17/11/2017, 4.0

**Chief Investigator:** Professor Freddie Hamdy, University of Oxford, Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Headington, Oxford, OX3 9DU  
tel: +44 1865 617123; fax: +44 1865 617125; email:  
Freddie.Hamdy@nds.ox.ac.uk

**Investigators:** Co-Principal Investigators:  
Professor Jenny Donovan, University of Bristol, Population Health Sciences, Bristol Medical School, 39 Whatley Road, Bristol, BS8 2PS; and  
Director of NIHR CLAHRC West, 9th Floor, Whitefriars, Lewins Mead, Bristol BS1 2NT; Tel: +44 117 3314599; email:  
Jenny.Donovan@bristol.ac.uk.  
Professor David Neal, University of Oxford, Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Headington, Oxford, OX3 9DU; tel: +44 1865 617126; email: david.neal@nds.ox.ac.uk.

Trial Co-Ordinator:  
Dr Athene Lane, University of Bristol, Population Health Sciences, Bristol Medical School, 39 Whatley Road, Bristol, BS8 2PS; and Co-Director BRTC; tel: +44 117 9287335; email: athene.lane@bristol.ac.uk.

**Sponsor:** University of Oxford

**Funder:** NIHR Health Technology Assessment Programme

**Chief Investigator Signature:**



There are no conflicts of interest.

## CONTENTS

1. SYNOPSIS .....	6
2. ABBREVIATIONS .....	7
3. BACKGROUND AND RATIONALE .....	8
3.1 Background to Study and Results of 10 Year Analyses .....	8
3.2 Benefits to the NHS .....	9
4. TRIAL DESIGN (Figure 1) .....	11
Actual trial recruitment and randomised numbers (Fig 1b) .....	12
5. AIMS .....	13
6. OBJECTIVES.....	13
7. STUDY DESIGN AND METHODS.....	13
8. ETHICAL ASPECTS .....	13
8.1 Ethics .....	14
8.2 Initial Ethics Committee Approval (CC) .....	14
8.3 Participant Consent (CC) .....	14
8.4 Investigator responsibilities (CC) .....	14
9. STUDY POPULATION AND PARTICIPANTS .....	14
9.1 Participant Enrolment .....	15
10. INCLUSION AND EXCLUSION CRITERIA .....	15
11. RECRUITMENT OF PARTICIPANTS .....	15
11.1 Recruitment Of General Practices (CC and Bristol).....	15
11.2 Participant Invitation Procedures (CC and Bristol) .....	16
11.3 Participant Visit Schedule (CC).....	16
12. PROSTATE CHECK CLINICS (PCC) .....	17
12.1 Initial Data Collection At The Prostate Check Clinic (PCC) .....	17
A. Research Nurse .....	17
B. Participants.....	18
12.2 Consent Form 3 ("Cooling Off" Consent) And Notification Of PSA Results (CC) .....	18
12.3 Eligibility For Diagnostic Phase Of The Study.....	19
13. THE DIAGNOSTIC PHASE (CC).....	19
13.1 Diagnosis Of Localised Prostate Cancer .....	19
13.2 Criteria For Trial Eligibility When PCC PSA Test Is <10ng/ml .....	20
13.3 Criteria For Trial Eligibility When PCC Or Biopsy PSA Is 10-19.99ng/ml .....	21
13.4 Criteria For Trial Eligibility When PCC PSA Is >19.99ng/ml.....	21
13.5 Data Collection At The Diagnostic Phase (CC) .....	21
13.6 Detection Of Localised Cancer At Biopsies Subsequent To Monitoring In Primary Care .....	24
13.7 Biopsy Classification And Interpretation Across Clinical Centres .....	24
14. ELIGIBILITY APPOINTMENT for APPOINTMENTS FOR PARTICIPANTS WITH CONFIRMED LOCALISED PROSTATE CANCER (CC) .....	24
14.1 Eligibility Criteria For Randomisation (CC) .....	24
14.2 Data Collection At The Eligibility Appointment (CC) .....	25

15. INFORMATION APPOINTMENT (CC).....	25
16. RANDOMISATION (CC AND BRISTOL).....	25
16.1 Minimisation Variables .....	26
16.2 The Main Study: The Three-Arm Trial.....	26
16.3 Alternative To Randomisation .....	26
16.4 Data Collection At Information Appointment (CC) .....	26
16.5 Data Collection After Treatment Allocation .....	27
17. TREATMENT (INTERVENTION) PROTOCOLS (CC) .....	27
18. ACTIVE MONITORING	
18.1 Treatment Details And Follow-Up Pathway.....	27
18.2 Assessing PSA Changes Over Time .....	28
18.3 Review Appointment And Annual Bone Scans .....	28
19. RADICAL PROSTATECTOMY.....	29
19.1 Treatment Details .....	29
19.2 Data Collection .....	30
19.3 Histopathological Staging And Evaluation .....	30
19.4 Positive Surgical Margins .....	30
19.5 Follow-Up Pathway .....	30
20. RADICAL CONFORMAL EXTERNAL BEAM RADIOTHERAPY v3.0.....	32
20.1 Treatment Details.....	31
20.2 CT Planning Requirements For Radiotherapy .....	32
20.3 Volumes And Dose Reference Point .....	32
20.4 Organs at risk .....	33
20.5 Simulation Procedures .....	33
20.6 Treatment Technique.....	33
20.7 Dose Computation .....	33
20.8 Dose Specification .....	34
20.9 Treatment Verification .....	35
20.10 Quality Assurance And Data Collection .....	35
20.11 Follow-up pathway.....	35
21. RECRUITMENT FLOW .....	36
22. RESEARCH DATA COLLECTION (CC AND BRISTOL) .....	36
22.1 Evaluation Of Detection (CC and Bristol) .....	36
22.2 Adverse Events (CC) .....	37
22.3 Pathology Findings (CC) .....	37
22.4 Follow-Up Timescale And Participant Group.....	37
22.5 Research Data Collection Of Treatments.....	38
22.6 Participant Data Collection At Six, 12 Months And Annually .....	38
22.7 Research And Other Data Collection At 12 Months And Annually (CC) .....	39
22.8 Survival Data.....	39
22.9 Extended Research Follow-up from 2018 to June 2021 .....	39
23. CLINICAL FOLLOW-UP (CC).....	40
24. OUTCOME MEASURES .....	40
24.1 Primary Outcome .....	40
24.2 Secondary Outcomes .....	40

25. ECONOMIC EVALUATION .....	41
25.1 Data Collection .....	42
25.2 Analyses.....	42
26. QUALITATIVE RESEARCH .....	43
27. DATA MANAGEMENT AND SECURITY.....	45
28. MANAGEMENT, MONITORING AND STUDY ORGANISATION .....	43
28.1 Trial Steering Committee 2012 .....	44
28.2 Data Monitoring Committee (DMC 2012) .....	44
28.3 Regional Management Committees .....	45
28.4 Study Management Committee meetings.....	45
28.5 Specialist sub-group meetings .....	45
28.6 Management Executive Committee .....	45
28.7 Departures from protocol.....	46
28.8 Organisation of study documentation .....	46
28.9 Study monitoring and SMART .....	46
28.10 HTA monitoring visits .....	47
29. PUBLICATION POLICY .....	47
30. QUALITY ASSURANCE PROCEDURES .....	47
31. ETHICAL AND REGULATORY CONSIDERATIONS .....	47
31.1 Declaration of Helsinki .....	48
31.2 Guidelines for Good Clinical Practice .....	48
31.3 Approvals.....	48
31.4 Reporting.....	48
31.5 Participant Confidentiality .....	48
31.6 Expenses and Benefits.....	48
32. FINANCE AND INSURANCE .....	48
32.1 Funding.....	48
32.2 Insurance .....	49
33. PROJECT MILESTONES.....	49
Year 1 .....	49
Year 2 .....	49
Years 3 to 5.....	49
34. REFERENCES	
APPENDIX 1: SETTING UP A NEW CLINICAL CENTRE.....	52
Training new centres for the information appointment and randomisation .....	52
APPENDIX 2: SAMPLE SIZE CALCULATIONS AND STATISTICAL ANALYSES (2012) AND UPDATED FOR EXTENDEND FOLLOW-UP (2018 TO JUNE 2021) .....	54
Sample Size Implications .....	54
Data analysis Plan.....	56
Primary Analysis .....	56
Secondary Analyses.....	56
Description of Statistical Methods (2018 to June 2021).....	58
The Number of Participants .....	58
Analysis of Outcome Measures .....	58
APPENDIX 3: PROGRESSION OF PARTICIPANTS THROUGH PROTECT STUDY .....	59

APPENDIX 4: AMENDMENT HISTORY .....	61
-------------------------------------	----

## FIGURES

Figure 1: Trial Design Flowchart (a original and b actual numbers) .....	11
Figure 2: The Clinical Diagnostic Process Before Eligibility Is Determined .....	23
Figure 3: Active Monitoring Follow-Up Pathway .....	28
Figure 4: Radical Prostatectomy Follow-up pathway .....	31
Figure 5: Radiotherapy Follow-Up Pathway .....	36

## Notes

1. All SOPs and additional protocols are available from the study coordinator
2. Study website: <http://www.bristol.ac.uk/population-health-sciences/projects/protect/>

**1. SYNOPSIS**

<b>Study Title</b>	The ProtecT trial – Evaluating the effectiveness of treatments for localised prostate cancer	
<b>Internal ref. no. / short title</b>	The ProtecT trial	
<b>Study Design</b>	Randomised Controlled Trial	
<b>Study Participants</b>	Around 110,000 recruited between 2001-2009	
<b>Planned Sample Size</b>	Around 2,600 in extended follow-up	
<b>Planned Study Period</b>	Until 30/06/2021 to include a 15 year median analysis	
<b>Objectives</b>	<b>Outcome Measures</b>	<b>Time Points</b>
<b>Primary Objective</b> To assess definite or probable prostate cancer specific mortality (and intervention-related mortality) at a median of 15 years following randomisation	Ascertainment by independent cause of death committee using vignettes compiled from medical note reviews and routine data and death certificates	Ongoing  On notification of death
<b>Secondary Objectives</b> At a median of 15 years  Overall survival  Disease progression and metastasis  Treatment complications  General health status, quality of life, symptoms (urinary, sexual etc), anxiety, depression and psychological state  Qualitative evaluation of outcome  Cost-effectiveness of	Death certificate data  Indicators of disease progression and complications of treatment from routine NHS data (PHE, PEDW and ISD). Verification by clinical record reviews where necessary  Validated PROMs for symptoms/treatment complications: ICSmaleSF, ICIQ, EPIC; psychosocial effects: HADS, POMS; cancer-specific QoL: EORTC QLQC-30 and overall QoL: SF-12, EQ-5D-3L  In-depth interviews with sample of participants in each arm and preference groups  Resource use from hospital and primary care and participant	Ongoing (unless stated otherwise)  On notification of death  Routine data every six months  Posted annually to participants  Interviews every two years or if disease progression  Completed at 10 year analysis

treatments	questionnaires	
Samples for basic science research (ProMPT) study	Annual blood sample (c. 50 mls) at NHS prostate cancer appointments	ProtecT research clinics completed

## 2. ABBREVIATIONS

CC	Clinical Centre
CI	Chief Investigator
CRF	Case Report Form
CTRG	Clinical Trials & Research Governance, University of Oxford
GCP	Good Clinical Practice
GP	General Practitioner
HRA	Health Research Authority
ISD	Information Services Division Scotland
MRC	Medical Research Council
MRI	Magnetic Resonance Imaging
NHS	National Health Service
NICE	National Institute for Health and Care Excellence
NIHR	National Institute of Health Research
OU	Oxford University
PCC	Prostate Check Clinic
PCT	Primary Care Trusts
PEDW	Patient Episode Data for Wales
PHE	Public Health England
PI	Principal Investigator
PIL	Participant/ Patient Information Leaflet
PROM	Patient Reported Outcome Measure
PSA	Prostate Specific Antigen
QoL	Quality of Life
R&D	NHS Trust R&D Department
REC	Research Ethics Committee
SOP	Standard Operating Procedure



TSC	Trial Steering Committee
UOB	University of Bristol

### 3. BACKGROUND AND RATIONALE

#### 3.1 Background to Study and Results of 10 Year Analyses

Prostate cancer is a major public health issue. The natural ageing of the population, combined with the continued and widespread use of improved diagnostic tests such as serum prostate specific antigen (PSA), are resulting in an increase in the numbers of men diagnosed with localised prostate cancer. In England and Wales, it is the second most common malignancy in men, with 6,179 new cases registered in 1971, rising to 17,210 in 1993.<sup>1</sup> Screening to identify prostate cancer while it is confined to the gland has provoked much public and scientific attention and there is intense debate about its role in improving men's health. While there are strong advocates of screening, the findings from most reviews of the scientific evidence conclude that there is insufficient evidence to recommend population screening because of the lack of evidence that prostate cancer screening would improve the quantity and quality of men's lives.<sup>2-5</sup> Particular concerns relate to the lack of knowledge about the natural history of screen-detected disease, and the lack of evidence about the effectiveness of treatments. In particular, no survival advantage has been shown for any major treatment, and each can result in damaging complications and outcomes, including incontinence and impotence for radical interventions and anxiety relating to the presence of cancer in "watchful waiting".

There have been several attempts to undertake randomised trials comparing two or more of the main treatments (radical prostatectomy, radiotherapy and watchful waiting), but each has suffered problems. Serious methodological flaws including failure to conduct an intention-to-treat analysis, pre-PSA detection of disease and high drop-out rates mean that it is not possible to rely on the two completed trials.<sup>6-8</sup> In the early 1990s, the UK MRC attempted to establish a trial comparing the three major treatments (PR06), which failed to recruit because of its reliance on incidentally diagnosed participants and the reported unwillingness of participants and clinicians to accept randomisation. A trial is currently underway in the US comparing early radical prostatectomy with observation (PIVOT),<sup>9,10</sup> but is experiencing difficulty in recruiting. There have also been more recent small-scale attempts to persuade participants to be randomised between the major treatments, but these have concluded that randomisation is not acceptable to men with prostate cancer.<sup>11,12</sup>

#### *Updated background (2017)*

The management of clinically localised and opportunistic screen-detected prostate cancer remains a highly controversial public health issue. In the UK in 2014, more than 45,000 new cases of prostate cancer were diagnosed, around 300,000 men were living with a prostate cancer diagnosis, and there were over 11,000 deaths.<sup>13</sup>

The NIHR ProtecT trial was designed to evaluate the comparative effectiveness and cost-effectiveness of active monitoring, radical prostatectomy and radical radiotherapy for clinically localized prostate cancer in terms of mortality, disease progression and patient-reported outcomes and experiences. Participants were recruited to ProtecT in nine UK centres between 2001 and 2009.<sup>14</sup> Over 220,000 men aged 50-69 years were invited for testing, 100,444 attended, 3,221 were diagnosed with prostate cancer. Of these,

2,664 had clinically localized disease, of whom 1,643 were randomised, and 997 selected their own treatment. In addition, 267 men with advanced prostate cancer and 290 men excluded from randomisation for other reasons were also followed up and there were also 279 men with a PSA of above 20 ng/ml. The primary outcome, prostate cancer-specific mortality at a median of 10 years' follow-up,<sup>15</sup> was reached on 23<sup>rd</sup> November 2015, in parallel with completion of a full 6-year follow-up for patient reported outcome measures (PROMs)<sup>16</sup> and a longitudinal qualitative study of men's experiences.

The ProtecT publications have had substantial impact and global attention, with over 300,000 downloads to date, 250 citations in less than 12 months, and almost 400 media stories, and included in the 12 most notable NEJM papers of 2016.<sup>17</sup> The clinical outcomes paper was listed as 22<sup>nd</sup> of 100 most impactful publications in 2016 according to Altmetric.<sup>18</sup> The US Task Force and NICE are now using these findings to revise their recommendations on the diagnosis and management of prostate cancer, and it is likely that clinical practice will change accordingly worldwide.

### **3.2 Benefits to the NHS**

Good evidence of treatment effectiveness should be available before there is widespread adoption of invasive treatments with potentially serious side effects. In localised prostate cancer, this is not the case. Despite the lack of evidence that radical treatment of early prostate cancer alters outcome, there is an increasing rate of detection in the general population through opportunistic PSA screening, and more men are offered treatment in the form of surgery and radiotherapy.<sup>19</sup> This represents an increasing burden on NHS resources, and is becoming a serious economic and ethical problem. Decisions are currently made by clinicians who tend to favour radical approaches, with patients who fear the consequences of living with an untreated cancer.<sup>19</sup> While the need for randomised controlled trials is not in doubt, difficulties in mounting such trials called for new methodological approaches which were employed in the Phase I feasibility study – methods which subject the clinical encounter itself to critical scrutiny and incorporates more fully the participant's perspective. The failure of other studies, including the MRC trial PRO6, which closed due to poor recruitment have been noted. There is a widespread view that participants are unwilling to be randomised to a non-radical treatment arm, a view that was shown in the feasibility study to be erroneous.

#### *Updated background (2017)*

Currently, based on the median 10-year findings from ProtecT, men, clinicians and policy-makers know that a man diagnosed with clinically localised prostate cancer will have a very low risk of dying from prostate cancer (~1%) whether they have radical treatment or active monitoring, but an increased risk of developing metastases with active monitoring compared with surgery or radiotherapy. What we do not know is whether or when this additional rate of developing metastases in active monitoring will be translated into an increased risk of dying of prostate cancer earlier than if they had surgery or radiotherapy, or whether the even higher risk of dying from other causes including cardiovascular disease and other cancers will intervene.


In addition, there are some small (but not significant) differences between surgery and radiotherapy in terms of primary treatment failure and biochemical progression which may or may not translate into

significant differences in metastases or progression. If this occurs by the median 15-year follow up, this would also change policy and practice. If these small differences favouring surgery turn into significant differences in the analyses with more years of follow-up, then the higher levels of sexual dysfunction and urinary incontinence could form a better trade-off. In active monitoring, there is a gain immediately from avoiding a loss of sex life and retaining continence, without knowing whether the higher risk of metastases will result in a shortening of life expectancy and the impact of the development of metastases and their treatment on quality of life.


While the analyses generated to date are informing men about the 'trade-off' between oncological outcomes for disease progression and side-effects of treatments in the short- and medium-term, longer follow-up is essential to provide information about mortality and disease progression. The research community has responded to our first outcomes' papers by calling for these longer-term data to be generated to inform global practice definitively.<sup>20,21</sup>

**Original text: 4. TRIAL DESIGN (Figure 1)**

*Original trial figure (Fig 1a)*



**Actual trial recruitment and randomised numbers (Fig 1b)**



## 5. AIMS

To evaluate the effectiveness, cost-effectiveness and acceptability of treatments for men with localised prostate cancer in a pragmatic randomised controlled trial. This trial will compare three treatments (active monitoring, radical prostatectomy and radical radiotherapy). The cost-effectiveness analysis was completed for the 10 year median analysis in 2016.

## 6. OBJECTIVES

- 1) To assess definite or probable prostate cancer specific mortality (including definite or probable intervention related mortality) at a median of 10 and 15 years following randomisation.
- 2) To investigate a number **of secondary**, including:
  - ◇ overall survival
  - ◇ disease progression (biochemical and clinical)
  - ◇ treatment complications
  - ◇ lower urinary tract symptoms
  - ◇ psychosocial impact of detection and treatment, including generic health status, quality of life and sexual function
- 3) Completed: To estimate the resource use and costs of case-finding, treatment and follow-up, and to compare costs and outcomes of treatment in terms of survival and health related quality of life up to the 10 year median analysis.
- 4) In routine NHS clinics: To collect samples suitable for basic science research (ProMPT study).

## 7. STUDY DESIGN AND METHODS

The treatment trial consists of two major components:

- 1) Early detection of prostate cancer with participants invited from general practices to attend prostate check clinics to be informed about the uncertainties of treatment and the implications of testing
- 2) A three-arm randomised trial of treatment for participants with localised prostate cancer

The 10 year median follow-up was published in 2016. Extended follow-up will continue until June 2021 to allow a 15 year median analysis. Follow-up will be largely passive (routine data and medical note review) and by participant questionnaires and is described in section 22.9

## 8. ETHICAL ASPECTS

*See revised section 31.*

## **8.1 Ethics**

The Investigator will ensure that this study is conducted in accordance with relevant regulations and with Good Clinical Practice.

## **8.2 Initial Ethics Committee Approval (CC)**

The principal investigator at each clinical centre (CC) will submit the protocol to the appropriate Local Ethics Committee for approval. The application for approval will include a copy of the participant consents, information sheets and other relevant materials. Approval has already been given by Trent MREC for ProtecT on 21st June 2001.

## **8.3 Participant Consent (CC)**

Persons asked to participate in this research are entitled to choose whether or not to take part. Their decision will be voluntary and they will be competent to understand what is involved. Consent forms will be designed to assure the protection of their rights.

Participants will receive both written and verbal information. The written information has been approved by the medically qualified investigators. The verbal explanation to the participant will be performed by the research nurse under the supervision of the medically qualified investigators. The verbal explanation will cover all the elements specified in the written information provided for the participant. The participants will be informed of the aims, methods, anticipated benefits and potential hazards of the study including any discomfort it may entail.

The participant will be given every opportunity to clarify any points he does not understand and if necessary ask for more information. At the end of the discussion the participant will be given time to reflect. The participant is at liberty to withdraw their consent to participate at any time, without prejudicing their future medical care.

The research nurse will then obtain the participants' freely given written informed consent for each stage of the study. Both investigators and participants retain copies of the signed consent forms.

## **8.4 Investigator responsibilities (CC)**

The principal clinical investigator at each centre will be responsible for the clinical conduct of the study staff. The clinical investigators will maintain a Trial Master File including a list and CVs of appropriately qualified persons to whom they have delegated significant trial-related duties. The investigator will be responsible that all such identified persons will be thoroughly familiar with the protocol and study procedures, as well as being aware of the principles of good clinical practice (GCP) (MRC Guidelines for Good Clinical Practice in Clinical Trials, MRC 1998). The Lead Nurse shall be appointed by the investigator at each centre and shall have responsibility for the efficient operation of the study to GCP guidelines (SOP Team Management).

## **9. STUDY POPULATION AND PARTICIPANTS**

## 9.1 Participant Enrolment

*Recruitment was completed in 2009.*

Participants will be recruited through general practices. In each centre, PCTs will be mapped and half the practices randomised to enter the ProtecT study. They will all be men within the age range 50-69 years. All such persons within the practices will be invited to attend for a PSA test to detect prostate cancer. Those men who have confirmed localised prostate cancer will be invited to participate in the treatment trial.

## 10. INCLUSION AND EXCLUSION CRITERIA

### Inclusion criteria

- Age 50-69\* years on the date of preparation of the list at the general practice of potential participants
- Male gender
- Able to give informed written consent to participate
- Fit for any of the three treatments and with a life expectancy of 10 years
- Registration with the participating general practice on the date of the PCC (registration with another practice after entry to ProtecT is not an exclusion criteria)

\*Invitation of age range 45-49 years pilot was conducted following MREC and LREC approval in one centre. Trent MREC approval 7th May, 2003.

### Exclusion criteria

This trial is of pragmatic design. Therefore, exclusion criteria will be kept to the minimum possible.

Participants will be excluded from entry if they have:

- Concomitant or past malignancies (other than a small treated skin cancer)
- Prior treatment for prostate malignancy
- Serious cardiac or respiratory problems in the previous 12 months of the PCC, i.e. stroke, MI, heart failure, COPD
- Kidney dialyses or transplantation
- Bilateral hip replacement
- Previous entry to the ProtecT study at a prior general practice

The presence of blood borne infections is not an exclusion criteria.

## 11. RECRUITMENT OF PARTICIPANTS

*Recruitment was completed in 2009*

### 11.1 Recruitment of General Practices (CC and Bristol)

Practices randomised to receive ProtecT will be contacted by the primary care researcher or the UK coordinator for general practices. The GPs and practice manager will be briefed about the ProtecT study, given the protocol and asked for consent for the practice to take part in ProtecT. An information pack will be sent out to each practice randomised to ProtecT, including details of the ProtecT website. The lead nurse will subsequently visit the practice to establish suitable accommodation for the study clinics and to liaise with practice staff. It is advised that practices are approached initially 3 months in advance of starting clinics. Practices may invoice for costs incurred in preparing the list of eligible men.



### 11.2 Participant Invitation Procedures (CC and Bristol)

There is a Setting up at new General Practices SOP. The clinical secretary will go to the participating GP surgeries and download the name, address, date of birth, NHS number and GP practice identification number of all men aged 50-69 years onto the study laptop computer. If possible, the list of men will have been previously screened by the practice for those unsuitable to participate and noted on the Access database. All individuals invited to participate in the trial will be allocated a unique study number by Bristol. Address labels will be generated and invitations to join the study sent to men in manageable batches (**Downloading protocol for clinical centres**). Letters are mailed out from the general practice on the practice headed notepaper. The data downloaded from the practice computer will only be saved at the practice. As each new practice is visited a record will be made of the doctor's names, address and contact details, computer system and total list size as well as the date of the first invitations on the downloading proforma. This information will be entered on the clinical databases and the proforma sent to the research coordinating centre (Bristol).

The reply slips are returned to Bristol and the names and addresses of men indicating their willingness to join the study will be entered on the project database along with the date on which the reply slip was returned. Men who telephone and indicate either their willingness to participate or refusal are recorded in the same way as for letters.

Those men who do not reply to the initial letter or who decline to participate on the reply slip will have no follow-up within ProtecT and their details will not be recorded on the main database.

Lists of men who are willing to participate are sent electronically via a secure network (NHSnet) to the clinical secretaries every two weeks. Secretaries in clinical centres will arrange appointments for these men and manage the prostate check clinic (PCC) lists, including rearranging appointments where necessary. A participant information sheet outlining the study will accompany the appointment letter (Information Sheet 1). The dates and times of the clinics and attendees will also be entered into the study database. Persons who do not/can not attend their intended appointment will be contacted by telephone and a further appointment organised with details recorded on the database. Should they not attend on 2 occasions it will be assumed that they no longer wish to participate and this will be documented on the study database. The PCC lists of appointments and place of the clinics will also be recorded on the database.

### 11.3 Participant Visit Schedule (CC)

- All participants: Prostate Check Clinic
- If raised PSA: TRUS and Biopsy
- If PSA PCC is 10-19.99 ng/ml and prostate cancer detected: Bone scan
- If localised prostate cancer: Eligibility appointment
- If eligible for randomisation:
  - Information appointment
  - Clinical follow-up: Active monitoring arm every 3 months in year 1 (see details section 16), other arms clinically determined (NHS care in extended follow-up and thereafter).

- Post-treatment: Research follow-up annually 12 months after randomisation
- Extended follow-up: See section 22.9 for details from 2018 to June 2021

## 12. PROSTATE CHECK CLINICS (PCC)

There is a PCC SOP. Recruitment will be performed mostly at the participating general practices, but also at the hospital. On attendance the research nurse (previously carefully instructed by the study team and working from a detailed script utilised in the training programmes) will provide verbal information on the study aims and design. Particular attention will be paid to the treatment phase of the trial. It will be made clear that only those who have localised prostate cancer will be requested to participate in the treatment trial. It will be stressed that the treatment is allocated at random by computer, unless the participant refuses randomisation and selects a treatment regime.

The clinical significance of prostate cancer will be discussed and it will be made clear that participation in the project is purely voluntary and the participant will be free to decline without prejudicing their future care. Participants will be given the opportunity to ask questions. Those who decline to participate will be free to leave and will be thanked for attending. They can have a PSA test if they so wish under current NHS recommendations, preferably with their GP. A letter is posted to their GP.

The research nurse will ensure that all men willing to participate in the trial are eligible to do so (using the eligibility criteria detailed earlier and in the PCC Schedule). Those ineligible to participate will have the reason for ineligibility explained to them and they will be thanked for their attendance and support of the project. They can have a PSA test if they so wish under current NHS recommendations, preferably with their GP. A letter is sent to their GP (Letter Excluded GP).

Men who wish to participate will be asked to give written, witnessed consent (Consent Form 1). Men have a further 24-hour period after the PCC clinic during which time they must sign and return a further consent form (Consent form 3) to agree to the PSA test being processed. A copy of all signed Consent documents will be given to participants.

Men are additionally asked whether they would like to participate in the ProMPT study (Prostate cancer Mechanisms of Progression and Treatment MREC 01/4/061). Men do not have to take part in ProMPT to enter ProtecT. The ProMPT study aims to establish the molecular pathology and mechanisms of tumour progression, develop novel treatment strategies and to evaluate novel markers and treatment approaches. There is an information sheet for the ProMPT study and consent form (Consent form 2), including consent for research on DNA. Trent MREC approved this study on 17 January 2002 and is ongoing to December 31<sup>st</sup> 2020.

### 12.1 Initial Data Collection at the Prostate Check Clinic (PCC) – *This data collection is complete*

#### A. Research Nurse

1. A SOP for the PCC details the full data collection procedures and nurse responsibilities.
2. Discusses study information, and requests consent to participate in the ProtecT and ProMPT study (Consents 1 and 2 in Schedule for Prostate Check Clinic).

- Consent form 1 is for consent to enter the study and take blood for the PSA test and future studies, including checking GP or hospital records
  - Consent form 2 is for consent for the ProMPT research
  - Consents 1 and 2 (one copy) are given to participant
  - A cross is placed in boxes of sections the participant does not consent to, initialled by the participant
3. Completes the S1 Schedule for Prostate Check Clinic containing:
- baseline socio-demographic data; age, socio-economic status, ethnicity
  - baseline clinical data, e.g. previous urinary problems or PSA tests
  - exclusion criteria checklist
  - a checklist to discuss with participants describing the ProtecT and ProMPT studies
4. Completes a single page version of the data entry form (PCC Proforma) about the attendance at the clinic and outcome. The PCC Proforma is entered onto the study computer at the earliest opportunity by the clinical secretary. Any potential problems with conducting a biopsy, e.g. allergies to penicillin, warfarin etc. are written on the reverse of the sheet as are any other comments regarding the man or the appointment.
5. Checks the participant's case notes if previous PSA tests have been performed and records the results on the form.
6. Records on the PCC Schedule their weight, blood pressure and pulse as well as the study instrument number of the scales and blood pressure monitor. If the blood pressure is above a hypertensive level agreed with the current practice (identified by the lead nurse in initial visits) the participant will be advised to have the blood pressure checked again by the practice nurse and the practice will be informed of the reading.

If men consent to the PSA test, the nurse takes blood as detailed in the **ProMPT Blood Collection and Storage Protocol**. Laminated sheets of relevant sections of the protocol are available for use in clinics.

## B. Participants

1. Men complete a study questionnaire (MTQ1) on urinary symptoms (ICSmaleSF *questionnaire*<sup>22</sup> ICIQ questionnaire), general health status (SF-12),<sup>23</sup> Hospital Anxiety and Depression scale<sup>24</sup> (HAD), EuroQol EQ-5D<sup>25</sup> Profile of Moods States and Impact of Events scale<sup>26</sup> which they may return in the post if necessary, using a freepost envelope.
2. Men are given a questionnaire (MTQ1a) with a freepost envelope to complete at home on environmental exposures and prostate cancer for the ProMPT study.
3. 30,000 men over an 18 month period will be given seven day dietary diaries (MTQ1b). The diet diaries will be sent to Bristol for coding and data entry.

## 12.2 Consent Form 3 ("Cooling Off" Consent) and Notification of PSA Results (CC)

Men have a further 24-hour period after the PCC clinic during which time they must sign and return a further consent form (Consent form 3) to agree to the PSA test being conducted on their blood sample. If men agree, the PSA test is conducted and the results entered onto the project database by the

secretary. A photocopy of the consent form is posted to the men and a copy may be held locally with the original returned to Bristol. Participants who telephone are asked to return their consent form by post. Men who do not complete the forms in full are requested to do so by post with the incomplete form posted back (Letter Consent3/retP). If participants do not return this form after being contacted by telephone or letter (Letter Consent3/NRP), or do not consent to PSA testing (Letter Consent3/refP), or do not sign the form, or are ineligible for ProtecT at the PCC, their blood specimens will be destroyed. This information is recorded on the study database. In the case of a non-reply, blood is destroyed one month after the date of the PCC.

All participants will receive the test results by post. The majority (~90%) of participants will have a normal PSA result (i.e. <3.0 ng/ml) and will exit the study (Letter NormP). The participant's GP will be informed of the test results (Letter NormGP).

Consent 3 also seeks further consent for the ProMPT research. Blood for this study is destroyed if Consent 3 is not obtained in the methods as described above.

All men with negative PSA results should have their ProtecT study data returned to Bristol for data entry and storage at this stage, i.e. PCC [S] schedule, MT1 questionnaire, Consent 3, grouped inside PCC schedule and recorded on the front of the PCC schedule.

### 12.3 Eligibility for Diagnostic Phase of the Study

- Men with a raised PSA result  $\geq 3.0$  ng/ml<sup>27</sup> and <20 ng/ml from the PCC PSA test
- Men with a raised PSA result of are >19.99 ng/ml are only eligible for a ProtecT biopsy if a reason for the raised PSA at PCC is identified e.g. prostatitis. If they have a convincing diagnosis of prostatitis, the PSA should be repeated before deciding on a biopsy

## 13. THE DIAGNOSTIC PHASE (CC)

*Diagnosis of prostate cancer was completed in 2009*

### 13.1 Diagnosis of Localised Prostate Cancer

All men with a raised PSA result (section 10.3) are invited to attend the Urology department of the clinical centre (Letter ab-lowP). There is a Diagnostic Process SOP. The participant's GP will also be informed (Letter ab-lowGP). The dates of the appointment and the attendance will be recorded on the study database. Locally approved protocols should be utilised for inviting men to biopsy who are on warfarin. The PCC proforma will be reviewed prior to biopsy e.g. for medication and whether to collect additional blood if 44 mls were not obtained at the PCC. Consent for the biopsy will be obtained using local Trust consent forms appropriate for the procedure.

At this appointment they will have a:

- TRUS-guided biopsy (10 cores)<sup>28-30</sup> under antibiotic prophylaxis according to local protocols
- physical examination including digital rectal examination (DRE)
- second PSA test (subsequent action will be taken only on the basis of the PCC PSA test unless a reason for the raised PCC PSA is identified e.g. prostatitis)

- a consent form (Consent 3.1) to request biopsy tissue for the ProMPT study to be used in conjunction with the ProMPT 'patient information sheet for ProtecT patients'

**All other tests required to determine eligibility for the ProtecT trial must be completed before the eligibility appointment, preferably within 4 months of the PCC date.**

There are several routes through the diagnostic/eligibility phase, depending on PCC PSA level and subsequent test results – each is detailed below (see also Figure 2).

### 13.2 Criteria for Trial Eligibility when PCC PSA Test is <10ng/ml

All men should proceed to a TRUS-guided biopsy, with DRE and second PSA test.

- (a) Men diagnosed with histologically-proven **clinically localised prostate cancer** (T1-T2, NX, M0) (2002 TNM classification),<sup>31</sup> are eligible for the treatment trial (section 14). If **high grade cancer (Gleason score 8-10) is found an isotope bone scan** should be conducted before the eligibility appointment.
- (b) Men with any suspicion of **advanced disease** should be investigated fully and if advanced prostate cancer is found, the man is ineligible for the trial and should be treated routinely, but details of the diagnosis to be added to the trial database (see Section 13.5).
- 
- (c) Men with **negative results** after the first biopsy require the following further tests to determine eligibility:
- Men with **HGPIN [high grade prostatic intra-epithelial neoplasia]** or **suspicious** findings should be offered a repeat biopsy immediately, as ~50% will have an associated invasive prostatic adenocarcinoma.<sup>32</sup> A letter is sent to the participant's GP and the participant.
  - Men with **inadequate biopsies** should be offered a repeat biopsy immediately. A letter is sent to the participant's GP and the participant.
- (d) Men with a negative **set of biopsies** should have their **free/total PSA ratio** measured [performed in Sheffield on a monthly basis, with samples sent on dry ice, preferably Tuesday–Thursday, with study centre and study no, name, forename, DOB, date of sample. Letters are sent to the participant and their GP (Letter neg-biopsy/PSAhighP, Letter neg-biopsy/PSAhighGP).

Further action depends on the result of the free/total PSA:

- (i) Men with a **free/total PSA ratio of 0.12 or less** (12% or less) will be offered a **second set of biopsies**.<sup>33,34</sup> If the repeat biopsy indicates localised prostate cancer, they will be eligible for the treatment trial. If the repeat biopsy is negative, the participant should be asked to return to UOP [Urology out-patients] for another PSA test, 12 months after the initial measurement at the PCC. If, at this time, PSA has doubled within 12 months, another biopsy should be offered; otherwise, annual PSA tests should be offered at UOP (Letter neg-biopsy/UOP/PSArepeatGP and Letter neg-biopsy/UOP/PSArepeatP).
- (ii) Men with a **free/total PSA ratio of >0.12** (greater than 12%) will be offered a **PSA 12 months after the initial test at the PCC**. If, at this time, PSA has doubled within 12 months, another biopsy should be offered; otherwise, annual PSA tests should be suggested conducted by the participants GP. A letter is sent to the participants' GP and the participant (Letter neg-biopsy/GP/PSArepeatGP and Letter neg-

biopsy/GP/PSArepeatP). PSA tests can be conducted in secondary care if the urologist prefers (Letter neg-biopsy/UOP/PSArepeatGP and Letter neg-biopsy/UOP/PSArepeatP).

Within the ProtecT study, annual PSA tests should not be offered once the participant is 70 years. Participants should be managed in primary care using standard NHS recommendations.

If, at any time in the diagnostic phase, men are diagnosed with histologically-proven clinically localised prostate cancer (T1-T2, NX, M0) defined according to the 2002 TNM classification, they are eligible for the treatment trial and should proceed to an eligibility appointment (go to section 14).

### 13.3 Criteria for Trial Eligibility when PCC Or Biopsy PSA is 10-19.99ng/ml

All men should proceed immediately to a **TRUS-guided biopsy**, DRE and second PSA test. The following action should be taken according to outcome:

- (a) If biopsy is inadequate, a repeat biopsy should be offered immediately
- (b) If first biopsy is **negative** or shows **HGPIN or is suspicious**, a second biopsy should be conducted immediately without free/total PSA measure. If biopsy 2 is negative and PSA remains high or rising in the absence of obvious other reasons, a 3<sup>rd</sup> and, if necessary 4<sup>th</sup>, set of biopsies should be undertaken by the most experienced member of the team and targeting the transitional zone, using GA if required (pathology to be informed of targeted biopsies). If all biopsies are negative, PSA should be repeated every 6 months for two years, with further biopsies indicated if doubling time is within 12 months.
- (c) An isotope bone scan is undertaken if cancer is detected histologically. If the bone scan indicates **skeletal metastases**, the man is ineligible for the trial and should be treated routinely but details of the diagnosis to be added to the trial database (see Section 13.5) (letter advanGP).
- (d) If the bone scan is negative and **clinically localised prostate cancer** (T1-T2, NX, M0) is diagnosed, men are eligible for the treatment trial (go to section 14).

If, at any stage, clinically localised prostate cancer (T1-T2, NX, M0) is diagnosed, the man is eligible for the treatment trial.

### 13.4 Criteria for Trial Eligibility when PCC PSA is >19.99ng/ml

Men with PCC PSA >19.99 ng/ml are likely to have advanced prostate cancer and will be dealt with urgently by the urologist, outside the ProtecT study, with the GP informed (Letter ab-highGP). Those found to have advanced disease are treated according to conventional practice, and are not eligible for the trial. A letter is sent to the participant's GP (Letter AdvanGP). Men with a PCC PSA of <20.0ng/ml and a biopsy PCC of >19.99ng/ml will be eligible for randomisation only if localised cancer is detected and a bone scan was negative. Information on disease grade and staging will be required for the CAP (**Cancer of the Prostate**) and ProMPT studies for all those with cancer who are ineligible for ProtecT and the details of those participants with cancer should be sent to the study coordinator.

### 13.5 Data Collection at The Diagnostic Phase (CC)


The research nurse completes onto the study computer at the earliest opportunity the clinical stage and grade of the disease, including Gleason scores, and whether other tests have been performed, e.g. bone scans or additional PSA tests. It is possible that there will be several appointments or events and results e.g. bone scans during the diagnostic phase, and data collection must occur at each appointment or event on all men with a raised PSA.

Participants are asked to complete questionnaire (Questionnaire MTQ2) containing similar measures used in the PCC clinic questionnaire (MTQ1) with the addition of the UCLA **EPIC** prostate cancer index.<sup>32</sup>  
<sup>35</sup> The questionnaire will be entered by Bristol. The questionnaire should be completed for each biopsy undertaken, including second or third biopsies.

If localised prostate cancer is diagnosed and the participant is excluded for any reason e.g. for health grounds, then this must be fully documented.

All men unable to proceed to the eligibility appointment for whatever reason should have their ProtecT study data returned to Bristol for data entry and storage, i.e. PCC schedule, MTQ1 and MTQ2 questionnaires, Consent 3, Consent 3.1, eligibility proforma grouped inside PCC schedule and recorded on the front of the schedule.

**Figure 2: The Clinical Diagnostic Process Before Eligibility Is Determined**





### 13.6 Detection of Localised Cancer at Biopsies Subsequent to Monitoring in Primary Care

Men with negative biopsies at entry to ProtecT who are later shown to have localised prostate cancer at subsequent biopsies, e.g. after a period in primary care, can have an eligibility appointment provided that they fulfil the study criteria for eligibility for randomisation (Section 12.1) and are still within the age criteria for the study.

### 13.7 Biopsy Classification and Interpretation across Clinical Centres

Quality control will be ensured by regular exchange of material for cross evaluation and confirmation of biopsy interpretations, led by Pathology Management Committee, expert pathologists from the clinical centres. There will be an audit of 5% of all TRUS biopsies. Data are collected on the biopsy and radical prostatectomy proformas and transferred to the clinical centres database by the research nurses. Urologists are requested to write right then left cores on biopsy forms to pathology. The ProtecT pathology classification scheme is:

<b>B1</b>	<b>Inadequate specimen (no prostate tissue identified)</b>	
<b>B2</b>	<b>Benign</b>	
<b>B3</b>	<b>Epithelial atypia not amounting to HGPIN</b>	
<b>B4</b>	<b>(tick either or both boxes as applicable)</b>	<b>Subcategory B4a: HGPIN</b> <b>Subcategory B4b: Atypical small acinar proliferation (ASAP)</b>
<b>B5</b>	<b>Adenocarcinoma</b>	

## 14. ELIGIBILITY APPOINTMENT FOR PARTICIPANTS WITH CONFIRMED LOCALISED PROSTATE CANCER (CC)

Men with confirmed localised prostate cancer are invited to attend an eligibility appointment **with the study urologist** (Letter DiagP and to their GP, Letter DiagGP). **All diagnostic tests and staging must be completed before the eligibility appointment.** This is a relatively short appointment in which the urologist explains the diagnosis, gives the participant an information sheet (Information Sheet 2) and invites the participant to attend a longer 'information' appointment with the research nurse (or the urologist if the participant requests) up to and no longer than 10 days later (unless the participant requests a delay). The feasibility study showed that this two-stage process is effective and efficient: men are often shocked by the diagnosis and need time to reflect on this and the advantages and disadvantages of the treatments before the trial randomisation ('information') appointment. Centres may also provide local audited figures for the side effects of treatments in addition to those provided in Information sheet 2. There is a Diagnostic Phase Summary Report that can be checked at this appt.

### 14.1 Eligibility Criteria for Randomisation (CC)

The urologist must ensure that all participants for randomisation fulfil these criteria:

1. Clinically localised prostate cancer (T1-T2, NX, M0) defined according to the 2002 TNM classification<sup>31</sup>

2. PSA at PCC in the range 3.0-19.99 ng/ml
3. No metastases from isotope bone scan (PCC PSA was 10-19.99 ng/ml or Gleason grade 8-10)
4. Fit for all three treatments (do not exclude on basis of age or cancer volume)

If the volume of cancer detected on biopsy is very small but the diagnosis is unequivocal, the case should be scrutinised with input from the pathologist but these patients are eligible for randomisation, and should NOT be excluded on the basis of tumour volume. The PIs are always happy to discuss these cases with the Urologist concerned as necessary.

#### **14.2 Data Collection at The Eligibility Appointment (CC)**

The urologist completes the eligibility schedule (S2 Schedule for Eligibility appointment), which records the clinical stage of the disease, whether the man is fit for all three treatment options and a checklist of issues discussed with the participants. Even if the participant has a strong preference for a treatment an information appointment should be arranged. If the information appointment does not happen, an information schedule is completed recording his selected treatment.

The whole consultation is recorded on tape unless the participant declines to allow the taping. There is a Recording SOP including digital tapes. At the end of the appointment, the tape is rewound and marked with the participants study number and placed in the locked cabinet identified for the study at the clinical centre. Audio tapes are sent to Bristol with the questionnaires and schedules on a regular basis and digital tapes by the NHS net. The tapes are booked in, transcribed and stored in a locked filing cabinet in Bristol.

#### **15. INFORMATION APPOINTMENT (CC)**

The main purpose of this information appointment is to provide the participant with sufficient information to allow him to decide whether or not he is willing to be randomised to the randomised controlled trial of active monitoring versus radical prostatectomy versus radical radiotherapy (3 arms).

The nurse-researcher emphasises the need for a trial of treatments, describes the advantages and disadvantages of each of the three treatments and explains the purposes of randomisation. The information content and delivery has been determined by the feasibility study and the nurse will work to a detailed but flexible script. Men should not undergo randomisation unless they are able to view all treatments as reasonably equivalent and at that stage randomisation should then proceed. There is an Information Appointment SOP.

#### **16. RANDOMISATION (CC AND BRISTOL)**

*Randomisation was completed in 2009.*

The participants give their written consent to be randomised (Consent form 4) and a copy of the form is given or posted to the participant (Consent 4 is not the acceptance of treatment allocated from the randomisation). Once the participant has given written consent to be randomised, the nurse will

telephone Bristol for the treatment allocation which will be performed in Bristol. The participant is told the allocation and asked whether he accepts it. He may want time to think or to talk to other clinicians.

### **16.1 Minimisation Variables**

- Participants' age on the date of the general practice list being made (and DOB for confirmation) (stratified into four 5 year age bands)
- Gleason score (stratified 2-4, 5-7 or 8-10)
- Average result of PCC and 1<sup>st</sup> Biopsy PSA tests (stratified <6, 6-9.9 or ≥10 ng/ml)

These variables and the man's study number are emailed to the nominated Bristol secretary when the eligibility and information appointments are arranged with the date of the appointment (copied to the trial coordinator).

If a participant had negative biopsies then re-entered the study after a period of PSA monitoring in primary or secondary care, followed by a positive biopsy, then the 2 latest PSA tests will be used for minimisation purposes.

If a participant is aged 70 years by the time of the PCC they will be entered as 69 years for minimisation purposes only.

If the Gleason sum score is missing it will be entered as 6 for minimisation purposes only.

### **16.2 The Main Study: the Three-Arm Trial**

The primary intention in the information appointment is to recruit informed participants to the main three-arm trial comparing active monitoring, radical prostatectomy and radical radiotherapy.

### **16.3 Alternative to Randomisation**

If randomisation is unacceptable to the participant, a participant-led selection of a treatment option will be reached without randomisation. These participants will be the 'selection group', including (rarely) if the participant does not have an information appointment.

### **16.4 Data Collection at Information Appointment (CC)**

The nurse will complete a Schedule for the Information Appointment (S3) which records a checklist of issues discussed with participants, and the decision reached regarding randomisation and the allocation for the participant. If the participant refuses to be randomised this is recorded. If further appointments are required, then the new appointment date is also recorded on the Schedule and the schedule is completed for each appointment.

The whole consultation is recorded on tape unless the participant declines to allow the taping. At the end of the appointment, the tape is marked with the participants' study number and placed in the locked cabinet identified for the study at the clinical centre. These tapes are sent to Bristol, as described in 14.2.

## 16.5 Data Collection after Treatment Allocation

All men are asked to be followed up, whichever treatment decision is reached, including selection participants. A letter is sent to the participant's GP indicating his treatment allocation (Letter RCTGP) or treatment selection (Letter PrefGP). Bristol are informed of the participant's treatment (study secretary and trial coordinator). The date of the treatment allocation acceptance is recorded in the Information Schedule (S3) and the centres database.

All men who have been randomised or have selected a treatment should have their ProtecT study data returned to Bristol for data entry and storage, i.e. PCC schedule, MTQ1 and 2 questionnaires, Consent 3.1, Eligibility and Information schedules, recorded on the front of the PCC schedule.

## 17. TREATMENT (INTERVENTION) PROTOCOLS (CC)

*The treatment phase of the trial is completed and all participants are under the clinical care of their local NHS team. **These treatments are to be given to participants either randomised to or selecting a particular treatment.***

All participants will receive a detailed study patient information booklet regarding the risks and benefits of the treatment regime to which they have been allocated or have selected, and the processes involved, including clinical follow-up. Locally produced information booklets may also be given to participants at this stage. Participants not indicating their choice of treatment or acceptance of allocation (by 6 months after randomisation) will be deemed to be on active monitoring until the participant indicates otherwise.

## 18. ACTIVE MONITORING

Men undergoing active monitoring will return for an appointment three months after randomisation to refine their plan of management. This appointment will usually be conducted by the research nurse and only staff connected with the study should undertake these appointments. PSA results, any additional tests or review appointments will be recorded on the Active Monitoring Treatment schedule (S4rAM) at each appointment. There will be an annual check of participant notes by the lead urologist to sign off the annual follow-up.

**18.1 Treatment Details and Follow-Up Pathway** - – See section 22.9 for details of extended follow-up

Their individual plan of management will be decided jointly by the participant and urologist or research nurse, but will include:

- PSA every three months in year 1, then 6 months thereafter
- Opportunity for a digital rectal examination (DRE) at the annual review appointment conducted by urologist as indicated (rise in PSA, new symptoms etc.)
- Opportunity for a review appointment (Section 16.2)

Prior to each follow-up visit, a PSA test will have been performed and results obtained so that at each visit, PSA results will be plotted and examined for any evidence of a rise that might indicate disease progression. Other factors that may cause increased levels, e.g. infection will also be investigated. The aim of active monitoring is to detect disease progression as early as possible, preferably while the tumour is still localised, but also to allow those whose disease remains stable to avoid intervention. The active monitoring pathway is shown in Figure 3.

### 18.2 Assessing PSA Changes over Time

Prior to each visit, the PSA test will be conducted so that the result can be plotted in the Active Monitoring Schedule. At each visit, the research nurse (or urologist) will assess the PSA results over the preceding 12 month period. If there is a rise in PSA level of 50% or more in that 12 month period, the participant will be asked to return for a repeat PSA test a minimum of six weeks and up to nine weeks later. Action is taken if the repeat PSA test confirms the 50% or greater rise over the original 12 months period, the participant will have a review appointment with the study urologist to discuss the implications of the rise and current options (see below). If the repeat PSA test does not confirm the previous 50% rise, the participant will return to regular Active Monitoring appointments. If at any time the nurse or participant is concerned about the PSA level, they may request a review appointment (see below).

**If a participant is concurrently prescribed the 5-alpha reductase inhibitor finasteride then the measured PSA value is doubled (measured is 6 ng/ml is taken as 12 ng/ml) and action taken on the doubled value.**

### 18.3 Review Appointment and Annual Bone Scans


A review appointment should be arranged with the study urologist in the following circumstances:

1. The PSA level has been assessed as defined above as 'rising'
2. If any symptoms of spreading disease (urinary or systemic) become apparent
3. If the participant or nurse is anxious about the PSA level or other concerns

At the review appointment, the study urologist will discuss the issues raised and current options, including remaining on Active Monitoring, undergoing re-staging of the cancer, or having other treatments, as appropriate. Other treatments might include radical prostatectomy or radiotherapy if the cancer still appears to be contained within the prostate. If the cancer is not contained within the prostate, treatment options would include transurethral resection of the prostate for bladder outflow obstruction, hormone treatment, radiotherapy and other relevant treatments.

**NB: Bone scans are conducted annually on participants once the PSA reaches at least 10 ng/ml. If the PSA remains at above this level the following year another bone scan is performed even if there has been no change in the PSA level.**

**Figure 3: Active Monitoring Follow-Up Pathway**



## 19. RADICAL PROSTATECTOMY

Participants undergoing radical prostatectomy will be listed for surgery optimally within 2 weeks, and no longer than 3 months, unless specifically requested by the participant for personal reasons.

Accurate per-operative data will be collected, including details of any complications. Standards of performance by the surgeons will be reviewed continually by the steering group.

### 19.1 Treatment Details

Participants will have the procedure explained in detail, as well as possible morbidity and complications. Participants will be admitted 24 hours prior to the surgery, which will only be performed by the surgeons involved in the trial. The steering group will ensure that these surgeons have a high level of expertise in performing the procedure by auditing retrospectively the results of their last 20 cases by the appropriate technique prior to involving them in the study. Alternatively, surgeons may elect to visit a centre of excellence in either Europe or USA to receive training. The TSC will be provided with anonymised surgeons' data. If any surgeons are outside acceptable limits, the TSC Chairman will be informed and will discuss the implications and necessary action with the PIs.

Pelvic lymphadenectomy and radical prostatectomy will be performed following the conventional anatomical retropubic approach as described by Walsh.<sup>36</sup> Laparoscopic and robotic prostatectomy approaches are also possible. The decision to undertake a nerve-sparing operation will be at the discretion of individual surgeons, depending on individual cases and after discussion with the participants. Prospective collection of data, outcome, rates of complications and results will be used for continuous monitoring of the quality of surgery performed. This is to ensure that the other treatment options are compared with the best possible surgical outcome. During surgery, participants will have their node status assessed:

- a) Those with a PSA less than 10 ng/ml and a Gleason score <8 will undergo pelvic lymphadenectomy and radical prostatectomy.
- b) Those with a PSA of 10 ng/ml or more and/or a Gleason score of 8 or over will undergo a frozen section biopsy of the pelvic lymph nodes prior to prostatectomy. If the lymph nodes are positive, the participant's further management will be at the surgeon's discretion.

## **19.2 Data Collection**

Accurate operative details will be recorded using the S4 Radical Prostatectomy Schedules (Surgeon) and (Researcher), including: length of the operation, blood loss, technical difficulties, unilateral or bilateral neurovascular bundle preservation, intra-and per-operative complications, the presence of urinary leaks or bleeding post-operatively, length of hospital stay and occurrence of any immediate post-operative complications, as well as general recovery from the surgery.

The participant will be discharged home and re-admitted 1-2 weeks later for trial without catheter. Continence will be assessed accurately at this stage, and if satisfactory, the participant will be allowed home, for further clinical follow-up at six weeks (histology) and 3 monthly.

## **19.3 Histopathological Staging and Evaluation**

This will be performed in a unified manner, with collaboration between respective histopathologists in the centres involved, using conventional tissue handling and histopathological criteria. Quality control will be ensured by regular exchange of material for cross evaluation, led by the lead pathologist.


## **19.4 Positive Surgical Margins**

This will be defined following conventional histopathological criteria. The association with capsular invasion and seminal vesicle involvement will be documented carefully. Adjuvant treatment (radiotherapy *and/or* hormonal manipulation) for these participants will be at the discretion of individual surgeons after discussion with the participant, and will be guided by PSA levels after the surgery.

## **19.5 Follow-Up Pathway - See section 22.9 for details of extended follow-up**

The follow-up pathway is shown in Figure 4.

**Figure 4: Radical Prostatectomy Follow-up Pathway**



## 20. RADICAL CONFORMAL EXTERNAL BEAM RADIOTHERAPY V3.0

The radiotherapy protocol has been written by M Mason, P Kirkbride, FC Hamdy, R Moore. Participants undergoing radiotherapy will receive 3-D conformal external beam radiotherapy. Radiotherapists with a special interest in uro-oncology will be responsible for this treatment, and their results audited retrospectively before and prospectively throughout the trial.

**This treatment protocol is to be given to participants either randomised to or selecting a particular treatment.**

### 20.1 Treatment Details

All participants will receive neoadjuvant hormone therapy for 3-6 months followed by external beam radiotherapy using 3D conformal methods. Participants will not be eligible to receive prostate brachytherapy, either as sole treatment or as a boost following external beam treatment.

Neo-adjuvant Androgen Deprivation will be achieved in all patients using LHRH agonists at four weekly cycles in conjunction with initial Cyproterone Acetate (CPA) or equivalent alternative, to prevent "flare phenomenon". The CPA or equivalent should commence approximately one week prior to the first LHRH



agonist injection and should be given for a total of at least three weeks. The duration of Androgen Deprivation should be at least three months and a maximum of six months, prior to commencement of radiotherapy and should continue until the end of radiotherapy.

## 20.2 CT Planning Requirements for Radiotherapy

CT planning scan should be done about 4 weeks before the commencement of radiotherapy.

Participants will be treated in the supine position. The bladder will be moderately full, (participant to drink about 500 mls 1 hr pre-scan) and the participant should be asked to empty the rectum as free of faeces and flatus as possible. No oral, rectal or intravenous contrast should be used.

Positioning/immobilisation will be using current departmental methods. Reproducibility of the positioning of the participants will be maintained using orthogonal laser beams or an equivalent method. The clinical and planning target volumes will be defined on CT scans, which will be taken at no more than 5 mm intervals (5 mm slice thickness). Scans will be taken from the bottom of the sacro-iliac joints to the penile urethra (usually 1 cm below ischial tuberosities will be adequate).

## 20.3 Volumes and Dose Reference Point

Clinical target volume (CTV) will be outlined by clinicians or authorised planning staff on CT scans taken in the treatment position as above. Outlining should be done on at least 12 (not necessarily contiguous) CT slices, so that the beam portal may accurately conform to the shape of the prostate, plus or minus seminal vesicles. The clinical target volume (CTV) can be accurately defined on CT images, however the planning target volume (PTV) is more difficult to define accurately and computer generated region growing algorithms are recommended to define the required margins. Volumes will be defined according to ICRU Report 50.<sup>37</sup>

Two groups of participants will be defined:

- **Group L** (low risk of seminal vesicle involvement)  
clinical stages T1b/c or T2a with  $(PSA + [(Gleason\ score - 6) \times 10]) < 15$
- **Group M** (moderate or high risk of seminal vesicle involvement)  
clinical stages T1b/c or T2a with  $(PSA + [(Gleason\ score - 6) \times 10]) \geq 15$   
or patients with clinical stage T2b

CTV will be defined on the basis of clinical and radiological staging as 1) either prostate and base of seminal vesicles or 2) to include prostate and all of the seminal vesicles. No deliberate attempt will be made to include lymph nodes, as adjuvant lymph node irradiation has not been shown to be beneficial.

	Phase I	Phase II
Group L	Prostate & base SV* (CTV <sub>1</sub> )	Prostate only (CTV <sub>2</sub> )
CTV	No margin beyond organ	No margin beyond organ
PTV	CTV <sub>1</sub> + 10mm	CTV <sub>2</sub> + 5 mm

Group M	Prostate & SV (CTV <sub>1</sub> )	Prostate only (CTV <sub>2</sub> )
CTV	No margin beyond organ	No margin beyond organ
PTV	CTV <sub>1</sub> + 10mm	CTV <sub>2</sub> + 5 mm

\*base of SV defined as 5mm margin, radially extended from the prostate defined.

## 20.4 Organs at Risk

Normal tissues may be outlined by authorised planning staff and will include bladder, rectum and femoral heads together with the body contour. The normal tissues will be outlined and considered as solid organs. Bladder should be outlined from base to dome. The rectum should be outlined from the anus taken at the level of the ischial tuberosities **or** 1 cm below the lower margin of the PTV, whichever is more inferior, to the recto sigmoid junction. This will give length of approximately 12 cm in most cases. Any additional bowel in the treated volume should be outlined separately.

## 20.5 Simulation Procedures

All treatment isocentres should normally be simulated for phases 1 and 2. After simulation the shape of the multileaf collimator (MLC) leaves or cerrobend blocks should be indicated on simulator films or digitally reconstructed radiographs (DRR). In the simulator, the position of the isocentre should be determined using orthogonal anterior and lateral fields.

## 20.6 Treatment Technique

The field arrangement for both phases will use a 3-field or a 4-field technique. A 4-field technique should only be used if the MLC movement plane is not in the same plane as the wedge. 3-field techniques should use anterior and left and right lateral fields (which may be modified with slight obliquity to left and right posterior oblique on an individual patient basis). 4-field techniques should use anterior/posterior and right and left lateral fields. 6-field techniques are not required.

If seminal vesicles are wrapped around rectum, then clinical advice should be taken from the consultant directing the treatment. Factors reported of consequence include patient age (younger patients may have increased risk of SV involvement), diabetes and more strongly, haemorrhoids (which may increase risk of rectal damage). Enclosing the rectum with >60% dose may increase rectal damage, and this is more likely in patients with a small rectal area in the transverse section. See recommendations in 18.8 Dose Specification.

The use of multisegment or IMRT solutions should be discussed with the trial QA group.

## 20.7 Dose Computation

Three dimensional dose distributions should be produced. Beam's eye view representations of PTV and organs at risk will be reproduced for each treatment beam and additionally in the mid-axial plane. If

there is marked variation in participant contour further axial distributions should be obtained 2 cm from the cranial and caudal field edges. Ideally, a mid-plane sagittal dose distribution should be produced.

Computer data representing dose distributions, CT images and contours should be archived. (Also see paragraph 18.10.)

## 20.8 Dose Specification

Dose prescription to participants will be 74 Gy in 2 Gy fractions; the phase 1 dose will be 56Gy in 28 fractions, and the dose to phase 2 will be 18Gy in 9 fractions. All doses are to be defined at the isocentre. All fields will be treated daily on a linear accelerator of 5 MV or greater. The planned overall treatment time will be 7.4 weeks. Phases 1 and 2 shall use shaped field throughout, with permission for up to total 5 (five) treatment rest days at any time during treatment. The rationale is that a) more departments have matched MLC linacs facilitating patient transfer b) use of open fields for phase 1 includes more rectum than use of open field for phase 2 (at same dose per fraction to isocentre). If more than 5 days gap is likely to occur, use of standard blocks positioned to approximate conformal shielding should be (virtual) simulated then treatment verified on treatment unit.

Minimum and maximum (area of at least 2 cm<sup>2</sup>) dose within the defined PTV would normally be 95% and 105% respectively. A hot spot dose outside the PTV will not exceed 105%.

Dose to organs at risk outside the PTV will not exceed the prescribed dose to the isocentre.

Dose volume histograms evaluating dose to CTV, PTV and organs at risk (rectum, femoral heads and bladder) shall be used to ensure the following dose constraints:

For bladder:

- <25% volume to receive dose >74Gy, i.e. 100%
- <50% volume to receive dose >67Gy, i.e. 90%

For rectum:

- Up to 3% of rectum permitted to receive  $\geq 74$ Gy i.e. 100% (3% represents rectal volume within PTV)
- <25% of rectum permitted to receive  $\geq 70$ Gy i.e. 95%
- <30% of rectum permitted to receive  $\geq 67$ Gy i.e. 90%
- <50% of rectum permitted to receive  $\geq 55.5$ Gy i.e. 75%
- Remainder of rectum permitted to receive  $\leq 44$ Gy i.e. 60%

Using sagittal reconstruction it is recommended that 60% isodose should not cross posterior rectal contour.

Cumulative dose to the femoral heads should not exceed a maximum dose of 55 Gy to a volume of  $\geq 2$  cm<sup>3</sup>. Dose corrections will be made for the femoral heads either on a pixel by pixel basis or using a standardised value of bone density. Departmental procedures concerning rectal gas shall be followed.

## 20.9 Treatment Verification

Orthogonal portal images or check films will be taken during treatment during phase I (3 or 4 field). When portal imaging devices are available daily images will be taken during week 1 and thence at weekly intervals. When using film at least 2 sets of images will be taken during the first week of treatment.

Port films will be compared to simulator images (or DRR). Treatment accuracy to within 2-3 mm is to be obtained whenever possible and positioning errors of 5 mm and greater are unacceptable. Corrections of participant positioning and appropriate resimulation will be employed if systematic errors greater than this magnitude are apparent. The departmental protocol shall include a specific number of observations on which resimulation is undertaken. (For example 3 observations of a discrepancy  $\geq 5$  mm).

## 20.10 Quality Assurance and Data Collection

Participants will be required to follow trial QA protocols as issued.

A questionnaire, planning consistency evaluation and dosimetry checks will form part of the quality assurance. Process documents will be produced by each participating centre, and a radiographer's log detailing verification data will be collected, using the format of the MRC RT01 study.

Data from the first 5 patients randomised since January 2003 must be printed on 'hard copy' and, additionally, in electronic format. Also, every subsequent 7<sup>th</sup> patient will be hardcopied. All trial patient plans should be archived and made available electronically.

Computer data representing dose distributions, CT images and contours should be archived. The data shall be exported in either native file format, DICOM-RT or RTOG format. They will be collected during one of the QA visits or via alternative systems (e.g. ISO 9660 CDROM or DAT UNIX tar, bru, compress, gzip). The data will be pseudo-anonymised when centrally stored. Data transfer and storage policy will follow the trial guidelines on data protection.

QA data will include:

1. Hardcopy and data representation of all outlining, target volume and critical organ definition.
2. Hardcopy and data representation of treatment dose distribution plans and dose volume histogram for all outlines defined.
3. Simulator images: copy films or scanned films or electronic images.
4. Verification images: copy films or scanned films or electronic images.

The data above will be submitted to the QA Physicist on a minimum six monthly basis or at prearranged collection visits.


## 20.11 Follow-up Pathway See section 22.9 for details of extended follow-up

Participants will be seen one month after completion of treatment, and thereafter 3-monthly for the first year, 6-monthly for the second year and then annually thereafter until disease progression (see below).

## 20.12 Disease Progression

The follow-up pathway is shown in Figure 5.

**Figure 5: Radiotherapy Follow-Up Pathway**



## 21. RECRUITMENT FLOW

*Recruitment completed in 2009.*

Each centre can recruit approximately 240 PCC attendees per month when the centre is fully established. 22 participants each month will have a raised PSA (11%) and will require a biopsy. 4 localised cases of prostate cancer will be identified per month (48 per year) and will be eligible for randomisation and follow-up.

## 22. RESEARCH DATA COLLECTION (CC AND BRISTOL)

*See section 22.9 for details of extended follow-up from 2018 to June 2021.*

All participants diagnosed with localised prostate cancer will undergo research data collection (comprehensive cohort principle). This includes those who were randomised, selected a treatment without randomisation, as well as those who sought therapies not offered by ProtecT, e.g. brachytherapy, or who are treated in private practice by any modality.

### 22.1 Evaluation of Detection (CC and Bristol)

*Recruitment and cancer detection completed in 2009.*

Clinical Research Protocol Template version 13.0

CONFIDENTIAL

© Copyright: The University of Oxford and Oxford University Hospitals NHS Foundation Trust 2016

Records will be kept of the response rates and the accuracy of the tests at each stage of the study. The positive predictive value of the PSA test will be calculated using histological confirmation as the 'gold standard'. The numbers and specific tests required by men with initially abnormal PSA levels (e.g. confirmatory PSA, TRUS with or without biopsy, bone scan) will be carefully documented to evaluate the urological workload, including those ineligible for randomisation.

## 22.2 Adverse Events (CC)

*There will be no adverse event reporting in extended follow-up from 2018 to June 2021.*

An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with this treatment.

Adverse events including treatment complications resulting from any of the three treatment arms will be recorded by the nurse on the diagnoses data entry form in the clinical centres database with the date of onset and resolution. Serious AE are defined by the MRC GCP guidelines:

Serious adverse events includes any **untoward** medical occurrence that:

- results in death
- is life-threatening
- requires in-patient hospitalisation or prolongation of existing hospitalisation
- results in persistent or significant disability or incapacity

All serious adverse events (SAE) should be notified within 48 hours of occurrence to the Chief Investigator and the study co-ordinator. Death notification should occur within 24 hours of the study team learning of the event. SAE probably related to participation in the trial are reported to the MREC within 15 days on the NRES SAE proforma. There may be a requirement from the local R&D office to report SAE, and this should be established by a centre.

## 22.3 Pathology Findings (CC)

*Diagnosis completed in 2009.*

All biopsy results of ProtecT participants will have a pathology biopsy proforma completed by the pathologist and data entered on the clinical centres database by the research nurses. The radical prostatectomy pathology proforma will also be completed and entered in the same way.

## 22.4 Follow-Up Timescale and Participant Group

*See section 22.9 for details of extended follow-up from 2018 to June 2021.*

**Research follow-up will be timed from the final information appointment (i.e. date randomised).** If there was no information appointment, the eligibility appointment is utilised. All localised cases of prostate cancer will undergo research follow-up, unless the participant withdraws completely from the study. Participants in whom disease progression to T3 or T4 occurs after randomisation will continue to have research follow-up unless the participant withdraws. There is a follow-up SOP covering Treatment and Research follow-up. Participants changing prostate cancer treatments should have the appropriate treatment schedule completed for the additional treatment. Efforts should be made not to "double count" events and to adhere to the annual timings of the follow-up.

## 22.5 Research Data Collection of Treatments

*See section 22.9 for details of extended follow-up from 2018 to June 2021.*

Data collection in each treatment arm will be timed around the commencement of the treatment regime. There are data collection schedules for each of the three treatment arms (S4 Schedules) collecting information on the procedures, complications and resource use. These schedules comprise:

Active monitoring: S4RAM sheet and chart completed at each visit

Surgery:

- S4Surgery surgeon completed on the date of surgery by the surgeon
- S4Surgery researcher, completed by the research nurse pre-and post-operatively and by the surgeon at 6 weeks post-surgery

Radiotherapy: S4RT Radiotherapy completed pre-radiotherapy by the research nurse, during treatment by the radiotherapy staff and at 6 weeks post-radiotherapy by the oncologist, including a radiographers log, completed by the radiographer during radiotherapy

Any biopsies conducted in follow-up should have a biopsy proforma completed by the pathologist and entered on the centres database.

## 22.6 Participant Data Collection at Six, 12 Months and Annually

*See section 22.9 for details of extended follow-up from 2018 to June 2021.*

Research data collection for the participants will commence 6 months after the date of the first information appointment, involving a postal questionnaire on resource use as well as the instruments used at baseline on anxiety and depression, urinary symptoms, sexual function and treatment related quality of life. Questionnaires (MTQ4) will be posted to participants after any changes of address or contact status are reviewed on the database by the clinical centres. A reminder is sent out 4 weeks after non-return of the questionnaire, including a small study token e.g. a ProtecT ballpoint pen. If there is no response and the details are checked and are correct at the clinical centre, the participant will be telephoned by the research or clinical centre 6 weeks after the original mailing. If no telephone contact is possible a short version of the quest (MTQ4a, MTQ5a and MTQ6a) will be posted recorded delivery. Methods to complete the questionnaire using a secure website will be developed, especially for those participants who have moved from the study centre. Participants potentially lost to follow-up will be traced using the NHS tracing service. The revised questionnaire also requests details of a second contact person for participants and these individuals will be contacted if other methods are unsuccessful. This person will also be contacted should the participant lose capacity to contribute to the study to ascertain the participants wishes regarding the study. There is a SOP Follow-up of men following treatment decision: Part III Questionnaire follow-up.

At 12 months and annually thereafter, participants will complete a version of the study questionnaire (MTQ5 and MTQ6), similar to that completed at six months.

## **22.7 Research and Other Data Collection at 12 Months and Annually (CC)**

*See section 22.9 for details of extended follow-up from 2018 to June 2021*

Full research data collection will take place at 12 months, and thereafter annually, after the date of the first information appointment.

Participants will be seen by one of the study nurses who will complete the Researcher 12 month (S5) or Annual Data Collection schedule (S6) based on the notes from the database and hospital notes as well as the participant interview. Research blood will be collected for urological research in those participants who have consented to this aspect of the study.

Men who move away should have a letter sent from the investigator to the local consultant detailing the study and enclosing the protocol. If the consultant is willing to send protocol based-PSA measurements to the clinical centre that would be continuing study follow-up. Research data collection should be obtained by telephone or by visiting the nearest study centre if feasible. The nurses will also request the details of a relative or partner who could act as a second point of contact should the participant be un-contactable by the usual means.

## **22.8 Survival Data**

*All participants who consented to flagging with national registries have been flagged with NHS Digital.*

All men participating in the study who give their consent to record flagging (Consent 1 in the S1 PCC Schedule) will be flagged at the UK National Health Services Digital to ensure that the primary outcome of the study, time ascertained at 10 and 15 years, can be analysed. Notification of mortality and cancer incidence amongst study participants will be achieved through flagging and through links with hospital pathology and clinical services in the ProtecT catchments and participating GP practices. Clinical centre staff will return to the general practices to obtain the NHS number of those men who attended the PCC to allow automated flagging. Notifications from NHS Digital will be entered on the study database.

## **22.9 Extended Research Follow-up from 2018 to June 2021**

Participants diagnosed with prostate cancer will be followed up in four ways:

1. Passive follow-up by notification of vital status from national registries.

Notification from NHS Digital several times annually to central research team for participants who consented to central registry flagging. Vignettes created for cause of death committee to ascertain the underlying cause of death using medical record review at centres by trial staff from the research centre and OU. Death certificate data will be used to derive overall survival.

2. Passive follow-up for clinical outcomes.

NHS routine data received several times annually by central research team. Outcomes will be derived from routine data by the central research team. Medical record reviews at centres will be targeted to supplement and validate routine data and will be conducted by research centre staff (UOB and UO) (and, if locally available, research staff at centres).

3. Participant questionnaires for patient-reported outcomes



A questionnaire is posted to participants annually from the research centre. A reminder is posted 4 weeks later and if there is no response the participant is telephoned by research centre staff around 2 weeks later. If no telephone contact is made a short version of the questionnaire is posted using recorded delivery at around nine weeks. The questionnaire can be completed online with the Research Data Capture (REDCap) system. The questionnaire asks for another contact person for participants and these individuals will be contacted if all other methods are unsuccessful. There is a SOP (Follow-up of men following treatment decision: Part III Questionnaire follow-up).

#### 4. Participant interviews

A sample of participants in each treatment group and of non-randomised men already recruited to a qualitative sub-study will be interviewed every two years (or if disease events occur) to evaluate men's experiences of outcomes and the implementation and acceptability of active monitoring. Interviews will be conducted either at UOB, or in men's homes or by telephone (as men prefer) by central research staff.

### **23. CLINICAL FOLLOW-UP (CC)**

*The treatment phase of the trial is completed and all participants are under the clinical care of their local NHS team.* Clinical follow-up will take place at 3-monthly intervals in the first year, and at clinical discretion thereafter. Clinical follow-up will be delivered by the specialist or their team (including the trial research nurses) undertaking the delivery of the treatment arms. These appointments will involve assessment of response to treatment, management of any complications, and investigation of any apparent disease progression. Any clinical follow-up is recorded as an event on the study clinical database in the follow-up module. Any PSA tests conducted in the radiotherapy arm up to 6 months post-treatment should be viewed with caution and the results may increase following cessation of hormone therapy.

### **24. OUTCOME MEASURES**

*Trial outcomes remain unaltered in extended follow-up, unless stated below*

#### **24.1 Primary Outcome**

The primary outcome is definite or probable prostate cancer specific mortality (including definite or probable intervention-related mortality) at a median of 10 and 15 years following randomisation.

#### **24.2 Secondary Outcomes**

- Overall survival at a median of 10 and 15 years follow-up
- Other outcomes at up to 10 and 15 years follow-up: disease progression; treatment complications; urinary and bowel symptoms, quality of life, sexual function, anxiety, depression and other psychosocial effects

These outcomes will be evaluated in the following ways:

Clinical Research Protocol Template version 13.0

CONFIDENTIAL

© Copyright: The University of Oxford and Oxford University Hospitals NHS Foundation Trust 2016

1. Prostate cancer mortality – An independent cause of death committee, blinded to the CAP allocation will be convened regularly to scrutinise vignettes and investigate/confirm the underlying cause of death.
2. Overall survival: cause of death from death certificates
3. Disease progression - using PSA, DRE, ultrasonography, biopsy, bone scans.
4. Treatment complications – (immediate complications relating to primary radical treatments have been completed by 2017 whilst long term complications are ongoing) delayed treatment complications including (completed: blood loss), rectal/bowel (completed: injury/) symptoms, sexual dysfunction, (completed: urethral stricture), incontinence, will be collected from routine data and in clinical schedules and participant questionnaires developed in the feasibility study.
5. General health status - measured by validated instruments: the SF-12, a subset of the SF-36<sup>23</sup>, and EuroQol EQ-5D.<sup>25</sup>
6. Anxiety, depression and psychological state - measured by the Hospital Anxiety and Depression Scale<sup>24</sup>, the Profile of Moods States<sup>26</sup>, and the EORTC QLQ-C30 questionnaire completed at (completed by 2017: ) ten years.<sup>39</sup>
7. Urinary symptoms - measured by the ICSmaleSF questionnaire<sup>22</sup>, which includes voiding and incontinence scores, nocturia, frequency and urinary-specific quality of life, the ICIQ questionnaire<sup>40</sup> the UCLA expanded prostate cancer index (EPIC).<sup>35</sup>
8. Sexual function - measured by the ICSsex questionnaire<sup>41</sup> and the UCLA EPIC.<sup>35</sup>
9. Quality of life (QoL) related to prostate cancer treatment – measured using the UCLA EPIC<sup>35</sup>.
10. Qualitative evaluation of outcome - assessed by in-depth interviews with samples of participants in each arm of the trial and also the preference groups.
11. Completed in 10 year analysis: Resource use (NHS, social service and personal). Routine hospital and primary care data sources with additional questions in clinical and participant questionnaires.

## 25. ECONOMIC EVALUATION

### *Completed in 10 year analysis*

The details of the economics aspects of the study are given in full in the ProtecT Economics Protocol: Evaluating the effectiveness of treatments for clinically localised prostate cancer. The economic evaluation will be conducted from the societal viewpoint as costs associated with the treatment and care of cancer participants may fall on participants, carers, social services and society in general, as well as on the NHS. The evaluation will also be performed using a long run perspective: this is most appropriate to any change in national practice. In this trial, all participants will essentially be receiving a higher level of care than would be usual practice. The aim within this trial is not to determine the efficiency of these treatments relative to current practice nor to determine the efficiency of prostate cancer treatment relative to other forms of health treatment. Rather, the aim is to provide an internal comparison of the three forms of treatment and to assign costs to the cancer detection.

The precise form of the economic evaluation will depend upon the outcomes of the trial. Initially outcomes of the alternative forms of treatment will be compared and consideration will be given to

performing a cost-effectiveness or cost-utility analysis. If, for example, there are differences only in survival, a cost-effectiveness analysis will be performed using years of life gained as the measure of outcome. If there are, additionally, differences in quality of life then a cost-utility analysis will be performed, with Quality-Adjusted Life-Years (QALYs) being used as the measure of outcome. These will be formed by combining information about survival with the EuroQol EQ-5D data collected annually, and participant utilities/willingness to pay data. The economic evaluation will be conducted after the main study assessments.

## **25.1 Data Collection**

During the trial, the direct costs falling on health services, participants, carers and social services as a result of treatment will be identified and collected. Although cancer detection costs will be the same in all arms of the trial, and are therefore not relevant to the decision about which treatment to perform, information about the costs associated with cancer detection will undoubtedly be useful to policy makers and will therefore be collected during the study. Physical resource use information collected will include: hospital stay, staff time, consumables, diagnostic tests, drugs, capital equipment, GP time and travel, participant and carer travel, out-of-pocket expenses, and any use of social services. Information about the indirect costs and benefits associated with time lost, from both work and leisure, will also be collected. These indirect costs will be presented separately. Routine information systems will be used wherever possible to collect information about both hospital and community services resource use. Resource and cost data from published literature and observational data sources will also be collected to assess whether there are differences between the trial population and routine practice. Where routine systems are available, resource use data will be collected for all participants. Where routine data systems are not available a combination of participant-held diaries and participant and carer questionnaires will be used to assess resource use on a sample of participants from across the centres over the recruitment period. Wherever possible, unit cost data generated within the hospital will be used to value resource use. Pro-rata salary will be used to value staff time. Unit costs of health and social services will be used as a source for the valuation of community/primary care services<sup>33</sup>. Time lost from work will be valued on the basis of average wages, lost leisure time will be evaluated at a proportion of time lost from work.

## **25.2 Analyses**

The analysis from the viewpoint of society will not include any transfer costs/payments. Discounting will be undertaken at 6% (with the discount rate varied during the sensitivity analysis). The economic data collected as part of the trial will be analysed to assess the mean costs, survival and health related quality of life for the specific trial population over the timeframe of the trial (1, 5, 10 and 15 years). This will give a reliable estimate of the relative value for money of the different treatments for the specific population, trial centres and trial protocol.

A sensitivity analysis will be undertaken (particularly given that much of the data will be collected in a somewhat artificial trial situation) and attention will be given to generalising the results obtained beyond the trial.

## 26. QUALITATIVE RESEARCH

*See section 22.9 for details of extended follow-up from 2018 to June 2021 as objectives 2 and 3 are ongoing*

The qualitative studies will include:

1. *Completed:* development and implementation of training methods, including tape-recording of information appointments and rapid feedback to ensure high levels of randomisation
2. *Ongoing:* detailed study of men's experiences of undergoing each of the treatments
3. *Ongoing:* evaluation of the implementation and acceptability of the active monitoring treatment programme
4. *Completed:* views and perceptions of urologists participating in the study.
5. *Completed:* Reasons of men refusing to participate in prostate cancer detection.

## 27. DATA MANAGEMENT AND SECURITY

*Some updating to processes in extended follow-up 2018 to June 2021*

A unique file identified by the study number will be maintained for participants. All data recorded on paper relating to the participant will be located in these files. A list will be maintained at each centre of staff with authorisation to make alteration to the study records, including the study database.

Data obtained on paper will also be entered onto and maintained on an electronic trial database. Information capable of identifying individuals and the nature of treatment received will be held in the database with passwords restricted to ProtecT study staff. Data from computerised sources will be converted to trial databases and hard copies will be maintained in the relevant participants file e.g. PSA results, in locked filing cabinets. Information capable of identifying participants will not be removed from Bristol or clinical centres or made available in any form to those outside the study. Data moved electronically from clinical centres to Bristol will only be sent by secure NHS networks or encrypted.

Routine NHS data will be held in a 'safe haven' on the UOB network, with access restricted to relevant trial staff. Importing, storage and use of routine data will comply with a System Level Security Policy between Public Health England and UOB.

The Clinical Centres' Database will be closed by 2018 (an archived copy will remain in a secure area of each centres' NHS Trust network) and moved to UOB.

All data held in Bristol will conform to the University of Bristol Information Security Policies and Compliance with the Data Protection Act policies.

The Trust's Caldicott Guardian should be informed at the commencement of the study in a clinical centre.

## 28. MANAGEMENT, MONITORING AND STUDY ORGANISATION

*See revised section 22.9 and below for extended follow up 2018 to June 2021*

A Trial Steering Committee and a Data Monitoring Committee will oversee the ProtecT trial. Written records will be taken of each meeting and copies held by the study coordinator.

### **28.1 Trial Steering Committee 2012**

*Continued in extended follow-up in revised format see below:*

- Chair: Professor M Baum (external surgeon, London)
- Professor A Zeitmann (external oncologist, USA)
- Professor D Dearnaley (clinical oncologist, London)
- Dr J Adolfsson (external urologist, Sweden)
- Professor P Albertsen (external urologist, USA)
- Professor T Roberts (external health economist, Birmingham)
- Dr M Robinson (ProtecT uro-pathologist, Newcastle-upon-Tyne)
- Professor M Mason (ProtecT oncologist, Cardiff)
- ProtecT Principal investigators (Professors Hamdy, Donovan, Neal)
- ProtecT senior statistician (Professor T Peters, Bristol)
- ProtecT coordinator (Dr A Lane, Bristol)
- ProtecT and CAP health economist (Dr S Noble, Bristol)
- ProtecT Coordinating Nurses (Mr P Holding, Sheffield; Ms T Lennon, Newcastle)
- Professor R Martin (CAP Principal investigator, Bristol)
- Dr E Turner (CAP coordinator, Bristol)
- Professor J Sterne (CAP senior statistician, Bristol)
- Professor F Schroder (CAP external urologist, The Netherlands)
- Professor T Walley (HTA Director)

The TSC will meet annually in January.

In the extended follow-up period a streamlined Committee with a new independent Chair Professor Peter Albertsen (University of Connecticut, USA) will meet annually by teleconference.

### **28.2 Data Monitoring Committee (DMC 2012)**

*The committee disbanded after their last meeting on 31/01/2015*

- Chair: Professor I Roberts (trialist, London)
- Professor D Ashby (statistician, London)
- Dr R Cowan (oncologist, Manchester)
- Mr T O'Brien (urologist, London)

Clinical Research Protocol Template version 13.0

CONFIDENTIAL

© Copyright: The University of Oxford and Oxford University Hospitals NHS Foundation Trust 2016

The DMC will be convened at any point when there are questions of safety or ethics in any part of the trial and will be the only body responsible for instigating an interim analysis of study data. They will review the safety and disease progression of participants in each treatment arm. The DMC will meet annually unless otherwise necessary. A report will be sent to the TSC with the recommendations from each DMC meeting. The TSC can invite the DMC Chair representative to attend the TSC.

### **28.3 Regional Management Committees**

*Now disbanded*

Each hub centre (Universities of Bristol, Cambridge and Oxford) will have a regional management committee comprised of the principal investigator based at that hub centre, urologists, oncologists, pathologists and lead nurses for each of centres associated with that hub. These committees will assist in monitoring the progress of the study at each centre. Written records will be maintained of these regional meetings and a copy sent to the study co-ordinator, who may attend these meetings as requested.

### **28.4 Study Management Committee Meetings**

*Now disbanded*

The principal investigators, urologists, oncologists, pathologists and lead nurses for each of centres may have meetings to feedback the TSC and DMC committee findings.

### **28.5 Specialist Sub-group Meetings**

*Now disbanded*

Specialist sub-group meetings will be held as determined by the sub-groups and PIs:

- Urologists: once per year
- Oncologists and radiographers: as required to include the radiotherapy link nurses
- Pathologists: once to twice per year
- Research Nurses:
  - Lead Nurses three times per year with research staff
  - All nurses: as required for training and updates
- Administrators: as required for all staff

### **28.6 Management Executive Committee**

*Continuing in extended follow up*

- Professors Hamdy, Donovan, Neal (not in extended follow up: Mason and Peters) comprise the committee

- All publications using ProtecT data must be approved by the committee prior to submission of the publication
- The committee retains the decision to publish or communicate study results
- The content of all presentations at scientific meetings using ProtecT data must be notified to the committee prior to presentation
- The details of publications and presentations at scientific conferences should be notified to the study coordinator and a copy of the paper sent on publication
- All additional studies with ProtecT participants must be approved by the committee prior to commencement, including ProtecT participants with negative biopsies. It is inappropriate for men to enter other urological-related randomised trials whilst in ProtecT follow-up.

## 28.7 Departures from Protocol

*During the extended follow up period:*

It is important to keep participant withdrawals from the trial to a minimum but;

- a participant may be withdrawn from the study by their general practitioner or the study team at any time should it be considered detrimental to the participant to continue.
- a participant may withdraw from the study at any time without prejudice to his subsequent treatment.

During the extended follow-up reasons for withdrawal will be documented on the study database.

*Completed:* Participants who fail to attend appointments will be contacted by telephone and letter, to encourage them to attend, to arrange alternative appointments and to determine reasons for withdrawal. Reasons for withdrawal will be fully documented on the study database and adverse event forms completed if applicable.

## 28.8 Organisation of Study Documentation

*In extended follow clinical centres will have a Site Investigator File which will be updated by central research staff.*

All clinical centres will have an investigators' Trial Master File which will include all relevant information and documentation for the trial. This will include the protocol, LREC approval, financial agreements, CVs of all staff involved in the trial, delegation logs and any correspondence or emails received pertaining to the study. It will be the responsibility of the lead nurse and clinical secretary at each site to maintain this file.

## 28.9 Study Monitoring and SMART

*Completed* The study will be also be monitored by the study co-ordinator and data managers through reports, visits and examination of the study database. Visits to PCC and the study centres may occasionally be made by the research study team as part of the data quality assessments. The annual Site Monitoring and Review Team comprised of two Lead Nurses and the study coordinator will investigate the conduct of the study at each centre.

Clinical Research Protocol Template version 13.0

CONFIDENTIAL

© Copyright: The University of Oxford and Oxford University Hospitals NHS Foundation Trust 2016

## 28.10 HTA Monitoring Visits

### *Completed*

The HTA may make annual monitoring visits regarding the conduct and progress of the study. The meeting will take place immediately following the TSC.

## 29. PUBLICATION POLICY

.....

***Continuing in extended follow-up with updates shown*** Brief annual reports will be produced for the NIHR HTA. Papers will be prepared for publication in general and urological peer-reviewed journals. The findings will also be presented at national and international conferences. The primary analyses will be undertaken when there is a median of 10 and 15 year follow-up (i.e. end of year 13 and 18). During the study, a number of other publications have been published such as the effectiveness of the training programme on randomisation rates, the accuracy of PSA tests, urological workload in terms of confirmatory tests required following PSA testing, short-and medium-term outcome following each of the treatments. There is a ProtecT publication policy available on the study website <http://www.bristol.ac.uk/population-health-sciences/projects/protect/which> describes the procedures to ensure the security of the primary and secondary outcome data of the ProtecT study, and promote analysis and publication of data through the study and other allied studies. Collaborators wishing to use ProtecT data for publication or collect additional data must complete a ProtecT publication or allied study request proforma (available on the study website) for approval by the ProtecT PIs.

## 30. QUALITY ASSURANCE PROCEDURES

### *In extended follow up from 2018 to June 2021*

The study may be monitored, or audited in accordance with the current approved protocol, GCP, relevant regulations and standard operating procedures. There will also be central monitoring and training of staff to ensure high quality data collection. The Trial Management Group (TMG) is comprised of the CI, Co-PIs and trial coordinator. The TMG will meet in person six-monthly and by skype/teleconference more regularly. The trial is supported by the Bristol Randomised Trials Collaboration, a UKCRC Registered Clinical Trials Unit, by providing research governance, statistical support and advice.

## 31. ETHICAL AND REGULATORY CONSIDERATIONS



*In extended follow up from 2018 to June 2021*

### **31.1 Declaration of Helsinki**

This study is conducted in accordance with relevant regulations and the principles of the Declaration of Helsinki.

### **31.2 Guidelines for Good Clinical Practice**

The Investigators will ensure that this study is conducted in accordance with relevant regulations.

### **31.3 Approvals**

The protocol, informed consent form, participant information sheet and participant questionnaires were submitted to an appropriate Research Ethics Committee (REC), and HRA for written approval. The Chief Investigator will submit and, where necessary, obtain approval from the above parties for all substantial amendments to the original approved documents.

### **31.4 Reporting**

The CI shall submit an Annual Progress Report to the NIHR, and once a year, or on request, to the REC Committee, host organisation and Sponsor. In addition, an End of Study notification and final report will be submitted to the same parties.

### **31.5 Participant Confidentiality**

Study staff will ensure that the participants' anonymity is maintained. Participants will be identified by a unique ID number on all study documents and any electronic database with clinical data, except for CRFs, where participant initials are added (and date of death if relevant) and participant questionnaires where men add their name to ensure correct logging on questionnaire return. The administrative details of participants are separated from clinical databases. All documents will be stored securely and only accessible by study staff and authorised personnel. The study will comply with the Data Protection Act which requires data to be anonymised as soon as it is practical to do so. Information capable of identifying participants will not be removed or made available to those outside the study.

### **31.6 Expenses and Benefits**

Reasonable travel expenses will be reimbursed on production of receipts, or a mileage allowance provided, as appropriate for participant interviews.

## **32. FINANCE AND INSURANCE**

*In extended follow up from 2018 to June 2021*

### **32.1 Funding**

The ProtecT study is funded by the NIHR Health Technology Assessment Programme (96/20/99).

### 32.2 Insurance

The University of Oxford has a specialist insurance policy in place which would operate in the event of any participant suffering harm as a result of their involvement in the research (Newline Underwriting Management Ltd, at Lloyd's of London).

## 33. PROJECT MILESTONES

*Completed at end of recruitment in 2009*

.....

### YEAR 1

- ◆ Continue full-scale recruitment in Sheffield, Newcastle and Bristol
- ◆ Train three new centres from September 2001 to March 2002 (Birmingham, Cardiff, Edinburgh)
- ◆ Train three new centres from March to September 2002 (Leeds, Leicester and Cambridge) if requirements are complied with, e.g. availability of 3-D conformal radiotherapy
- ◆ Initiate 6-monthly meetings of steering group to evaluate recruitment, co-ordination between centres and data quality control.
- ◆ Follow-up of all participants to be continued throughout lifetime of study

### YEAR 2

- ◆ Continue full-scale recruitment in Sheffield, Newcastle, Bristol and three centres commencing in year 1, with increasing recruitment in the next three centres

### YEARS 3 TO 5

- ◆ Continue full-scale recruitment in all nine centres – to be completed at the end of year 5

## 34. REFERENCES

1. Majeed A, Babb P, Jones J, Quinn M. *BJU Int* 2000;85:1058-1062.
2. Wasson JH, Sushman CC, Bruskewitz RC, et al. *Arch Fam. Med* 1993;2:487-93.
3. Editorial. UK experts advise against prostate cancer screening. *Lancet* 1997;349 (9050):1-2.
4. Woolf SH. *BMJ* 1997;314:989-90.
5. Neal DE, Donovan JL. *Lancet Oncology* 2001: 17-24.
6. Paulson DF, Lin GH, Hinshaw W, Stephani S. *J Urol* 1982;128:502-5.
7. Graverson PH, Nielsen KT, Gasser TC, et al. *Urology* 1990;36:493-8.
8. Madsen P, Peder H, Gasser TC, Corle DK. *Scand J Urol Nephrol* 1988; 110: 95-100.
9. Wilt TJ, Brawer MK. *J Urol* 1994;152:1910-4.
10. Wilt TJ, Brawer MK. *Semin Urol* 1995;13:130-6.
11. O'Reilly P, Martin L, Collins G. *BMJ* 1999;318(7197):1556.
12. Livesey JE; Cowan,RA; Brown,CW. *Clinical Oncology* 2000; 12:63.
13. *Prostate cancer incidence statistics*. 2014; Available from:  
<http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence>.
14. Lane JA, Donovan, JL, Davis M, et al. *Lancet Oncol*, 2014;15:1109-18.
15. Hamdy FC, Donovan JL, Lane JA, et al. *N Engl J Med*, 2016;357:1415-24.
16. Donovan JL, Hamdy FC, Lane JA, et al. *N Engl J Med*, 2016;357:1425-37.
17. NEJM. *Notable Articles of 2016*. 2016; Available from:  
<https://anesthesia.ucsf.edu/system/files/NEJM%20Notable%20Articles%202016.pdf>
18. Altmetric. *Top 100 Articles of 2016*. 2016; Available from:  
<https://www.altmetric.com/top100/2016/>
19. Donovan JL, Frankel SJ, Faulkner A, Selley MA, Gillatt D, Hamdy FC. *BMJ* 1999; 318:299-300.
20. Albertsen P. *Journal of Urology*, 2016;196:1604-05.
21. D'Amico AV. *J Clin Oncol*, 2017;35:1638-40.
22. Donovan JL, Peters TJ, Abrams P, Brookes ST, De La Rosette JJ, Schafer W. *J Urol* 2000;164:1948-55.
23. Brazier JE, Harper R, Jones NMB, et al. *BMJ* 1992; 305:160-164.
24. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand* 1983; 67:361.
25. The EuroQol Group. EuroQol - a new facility for the measurement of health. *Health Policy* 1990;16:199-208.
26. Shacham S. *J Pers Assess*, 1983;47:305-6.
27. Schröder FH, van der Crujsen-Koeter I, de Koning HJ, et al. *J Urol* 2000;163(3):806-12.
28. Babaian RJ, Toi A, Kamoi K, et al. *J Urol* 2000;163:152-7.
29. Presti JC Jr, Chang JJ, Bhargava V, Shinohara K. *J Urol* 2000;163:163-6; discussion 166-7.
30. Borboroglu PG, Comer SW, Riffenburgh RH, Amling CL. *J Urol* 2000;163:158-62.
31. Hermanek P, Sobin LH, Wittekind C. *TNM Classification of Malignant Tumours (UICC S.), 2002*.
32. Häggman MJ, Macoska JA, Wojno KJ, Osterling JE. *J Urol* 1997; 158: 12-22.
33. Catalona WJ, Partin AW, Slawin KM, et al. *JAMA* 1998 20;279:1542-7.

34. Patel D, White PA, Milford Ward A. *BJU Int* 2000;85(6):686-9.
35. Wei JT, Dunn RL, Litwin MS, et al. *Urology*, 2000;56:899-905.
36. Walsh PC. *Campbell's Urology*. Ed. Walsh PC, Retik AP, et al. WB Saunders. Philadelphia. pp 2865-2886.
37. Lahtinen T, Tenhunen M, Vayrynen M. *Radiother Oncol* 1993;28(2):174-6.
38. Hamdy FC. *Lancet Oncology*, 2011;12:832-3.
39. Aaronson NK, Ahmedzai S, Bergman et al. The EORTC QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. *JNCI* 1993;85:365-76.
40. Avery K, Donovan JL, Peters TJ et al. *Neurourol Urodyn*, 2004;23:322-30.
41. Frankel SJ, Donovan JL, Peters TJ et al. *J Clinical Epidemiology*, 1998; 51(8): 677-685.

## APPENDIX 1: SETTING UP A NEW CLINICAL CENTRE

### *Completed at end of recruitment in 2009*

Resources have been provided by the NHS HTA Programme to support all research costs. Each clinical centre will be sub-contracted to one of the major research hubs (Bristol, Cambridge and Oxford). Resources will be obtainable by quarterly invoice in arrears to the hub centres. First wave centres will commence in September 2001; second wave in March 2002.

1. Lead nurse and secretary to be appointed as close to day 1 as possible. The lead nurse will be employed by the research hub, but all other staff will be appointed through the Trust.
2. Appointments and setting up of study to be assisted by the close involvement of the lead nurses from the research hubs. Assistance will also be provided by the ProtecT qualitative researcher.
3. Setting up ProtecT study SOP to be utilised.
4. Clinical centre' lead nurse (CCLN) to shadow co-ordinating nurses in the research hub for two days. Birmingham, Cardiff, Leicester and Leeds to Sheffield; Edinburgh and Cambridge to Newcastle.
5. CCLN to identify first practice, set up lab staff/procedures, TRUS/biopsy clinics, office procedures etc.
6. CCLN to schedule first prostate check clinic (PCC) appointments hourly in first instance. Two days' worth, then stop for discussion with co-ordinating nurses.
7. Two-day training programme for new nurses at Bristol, new secretaries and urologists if possible.
8. Two new nurses to be appointed by month 3. Secretary also to be appointed. One nurse to be appointed by month 9 to help with follow-up and PCCs.
9. The PIs and coordinator to work with urologists and lead nurses over the first few months to ensure they are aware of the study details, budget arrangements and provide training for the eligibility appointments and the information appointments where participants request second opinions.
10. PCC appointments will be extended to 45 minutes during the training period. A minimum of 60 appointments per week, each lasting approximately 30 minutes, is expected when the centre is working at full capacity (i.e. after six months).

### **Training new centres for the information appointment and randomisation**

Full training for nurses and urologists will be based on the findings of the feasibility study. It is expected that at least 60-70% of participants will consent to randomisation following training. Training will include:

1. Initial 2-day course outlining the study procedures, need for a treatment trial, evidence about treatments, concepts and practicalities of randomisation, and practice in the delivery of the study information.
2. Observing information appointments led by training coordinator nurses in the research hubs - 'mentoring'.
3. Consenting to the tape-recording of 'information' appointments.

4. Receiving feedback and further training based on the analysis of the tape-recordings.
5. Accepting that the randomisation rate will be monitored and consenting to further tape-recordings and feedback during the progress of the study.

The training programme is based on the feasibility study.

If the randomisation rate is <60% after the first 6 months, every effort will be made by the ProtecT study team to increase recruitment to the acceptable rate required for the study sample size (minimum 60%). If this rate can not be reached an alternative centre will have to be found to replace the centre.

## APPENDIX 2: SAMPLE SIZE CALCULATIONS AND STATISTICAL ANALYSES (2012) AND UPDATED FOR EXTENDEND FOLLOW-UP (2018 TO JUNE 2021)

The latter part of the feasibility study showed that each centre can see approximately 200 prostate check clinic attenders and thus detect approximately 4 localised cases per month (48 per year). The table below indicates the numbers of eligible cases expected based on five years of recruitment in nine centres in total (i.e. six new centres in addition to the current three), assuming that each new centre will require six months of training and will operate at 0.5 efficiency over first 12 months.

Centres	Feasibility	Year 1	Year 2	Year 3	Year 4	Year 5
Current 3	150	144	144	144	144	144
4+5+6		72	144	144	144	144
7+8+9			100	144	144	144
Total	150	216	388	432	432	432
Cum.	150	366	754	1186	1618	2050

### Sample Size Implications

Sample size could be considered in terms of survival time or the proportion expected to survive after 10 years' follow-up. Although the former is preferable since it corresponds to the primary analysis, given the high proportions surviving for 10 years the power of these two approaches is virtually the same. Given the availability of data in the literature on the 10-year survival (around 85% for all treatments) and the greater transparency of such specifications, the following calculations are therefore presented in these terms. In time this will need to be revisited once sufficient numbers of events accrue: (a) for the figures to be presented more directly for the intended primary Cox regression analyses, and (b) for the study assumptions about such numbers of events to be reassessed in a similar fashion to that employed by the ATAC trial involving postmenopausal women with early breast cancer. In the meantime, for both the primary (intention-to-treat) analysis including all men randomised, and hence also for the purposes of considering the implications of the projected sample size, the crucial statistic is the 95% confidence interval for the difference in 10-year survival between any two of the three treatment arms.

Previously the central role of such confidence intervals was expressed in terms of demonstrating equivalence between the trial arms, but the present proposal is that it is better to take a more general view – that is, by considering the widths of projected confidence intervals for various scenarios. The first set of scenarios is to obtain the confidence intervals for a spread of possible observed differences (between the null and 10 percentage points), given the current projected total sample size of 2050 to be recruited by May 2006 (Year 5). An additional aspect considered for the first set of scenarios is the impact of a relatively conservative Bonferroni correction to the coverage probability of the confidence intervals, to account for the three pair wise comparisons being considered.

The second set of scenarios involves calculating the increases in the sample size that would be required in order to reduce the widths of such confidence intervals by 10% and 20% in relative terms. The third

set of scenarios explores the potential precision of the main (explanatory) secondary analysis – in particular, by calculating the confidence intervals for a simple ('per protocol' or 'on-treatment') analysis including only those who actually received their allocated treatment, assuming percentages for the latter of between 75% and 85%.

For all the scenarios, the figures initially presented are the numbers of men analysed (for the intention-to-treat analyses this is the same as the number randomised). Assuming the current overall rate of 70% of men agreeing to be randomised, the figures are then multiplied by about 1.43 to give the total number of men with localised prostate cancer who need to be identified by the detection.

In detail, then, for the first set of scenarios the confidence interval widths were calculated for the current projected sample size of 478 per arm for (again projected) observed differences of 0, 5 and 10 percentage points. In each case the overall percentage surviving 10 years was assumed to be 85% – for example, the difference of 10 percentage points related to a comparison of 80% versus 90%. However, the effect of altering the overall survival was investigated for selected situations by also considering 85% vs. 95%. In each case the margin of error is presented, calculated as usual as the 'half-width' of the confidence interval.

Within the range considered, the observed difference had negligible impact on the absolute margin of error, and hence just one figure is presented in the following table. Moreover, the 4.5% margin of error for 80% vs. 90% only reduces to 3.8% for 85% vs. 95%. It should nonetheless be noted that the implications of the levels of imprecision given below may well change across, for example, a confidence interval of –4.5% to 4.5% for an observed difference of 0% and one of 5.5% to 14.5% around a 10% difference. Adjusting for the three pairwise multiple comparisons has very little effect. (Although this has been conducted relatively crudely by just altering the (two-sided) significance level to 5% divided by 3 and hence the coverage probability to 98.3% for each contrast, if anything this approach would be expected to be conservative.) As can be seen from the second set of scenarios, sample sizes would have to be increased considerably to yield relatively modest reductions in the margin of error – for instance, to reduce it by 10% would require an increase of 25% in the numbers randomised, and for a 20% gain the increase is 60%. For each of the two assumed percentages of men adhering to their allocated treatment the third set of scenarios indicate that the (most conservative) secondary on-treatment analyses would have a margin of error of around 5% (with the 4.9% reducing to 4.1% for 85% vs. 95% surviving at 10 years).

Scenario		Margin of error	Number per arm analysed	Total number identified
Observed difference in range 0-10 percentage points	Ignoring multiple testing	4.5%	478	2050
	Adjusting for multiple testing	5.5%	478	2050
Reduce margin of error by a factor of:	10%	4.1%	≈ 600	2574
	20%	3.6%	≈ 750	3216
On-treatment analysis excluding departures from protocol (% included)	85%	4.9%	406	2050
	75%	5.2%	358	2050



## Data Analysis Plan

### Primary Analysis

The primary comparative analysis will be conducted on an intention-to-treat basis, comparing the three groups as randomised. For the primary analysis of survival (for a median of 10 years' follow-up), Cox proportional hazards regression will be used to obtain hazard ratios and their confidence intervals, adjusting for the four stratification/minimisation variables (centre, age, PSA and Gleason). Corrections for multiple comparisons between the three randomisation groups will be considered, by for instance using the Student-Newman-Keuls procedure.

### Presentation of the primary analyses

Treatment	10-year mortality risk	95% confidence interval
Surgery	a.bc	(j.kl, m.no)
Radiotherapy	d.ef	(p.qr, s.tu)
Active monitoring	g.hi	(v.wx, y.za)
<i>p-value</i>	<i>0.fg</i>	
<i>p-value</i>	<i>0.fg</i>	

This table will be supplemented by the Kaplan-Meier plots. The p-value is for the (overall) null hypothesis of equal risk across the three treatments. The hazard ratios and their 95% CIs for the three pairwise comparisons are then presented in a separate table or text, but pairwise significance tests are conducted if and only if the overall test yields a p value less than 0.05. This conditional approach keeps the overall false positive rate at 5%, and has been found to maintain power in simulation studies (Bauer, P. Multiple testing in clinical trials. *Statistics in Medicine* 1991;10:871-890.)

As a secondary analysis, the hazard ratio and 95% CI for both radical treatments (surgery and radiotherapy) combined versus active monitoring will be presented. Any p-value for this comparison would need to be corrected for multiple comparisons to maintain consistency between the primary and secondary analyses; the precise nature of this correction is to be investigated in further simulation studies.

### Secondary Analyses

Secondary analyses will include Cox regression for time to disease progression and logistic regression for survival at 10 years, and analyses of the various quality of life instruments employed within the trial. The latter are complicated by the fact that while men enter the ProtecT study in general terms healthy and asymptomatic, each treatment is likely to impact in different ways on particular physical, social and emotional measures. The principal quality of life measure has therefore been chosen as the SF-12 since it assesses generic health status and hence should apply equally across the randomised groups. The other important measures (of incontinence, sexual and bowel function, anxiety and depression) will all be analysed, but many of these will vary across the groups in relatively predictable ways. Further methodological work is envisaged and clearly required to investigate the importance placed by men themselves upon these various aspects of quality of life, both severally and in combination. The EORTC

QLQ-C30 is included to examine the impact of progression, and the EuroQoL EQ-5D to assess utilities for the economic evaluation. Adjustments will also be made for major imbalances between the arms at baseline by introducing appropriate covariates into all the regression models.

Planned subgroup analyses will be conducted by stratified analyses for descriptive statistics and formally by including interaction terms in the relevant regression models. These subgroup analyses will investigate differential comparisons across the randomisation groups according to the following patient characteristics: disease grade (Gleason score <7, 7-10), clinical stage (T1 vs. T2), age and PSA level (both as continuous variables). The 'Gleason score' will be obtained as the sum of the Gleason score for the most dominant pattern in the tumour and the score for the second most common pattern. For subgroup analyses based on continuous variables (age and PSA), departures from the assumptions of a linear relationship will be investigated by introducing polynomial terms, with a categorical version only considered if necessary on grounds of interpretability and provided there is no marked loss of power.

The secondary analyses will also estimate the relative efficacy of each treatment amongst individuals who do comply with their original allocated treatment. Such an estimate can be considered as a measure of the treatment's potential if, for example, compliance with treatment can be improved through a reduction in the risk of side-effects. Per protocol and on-treatment methods attempt to measure efficacy, but both are almost inevitably biased. Instead we will obtain unbiased estimates of efficacy amongst compliers using complier average causal effect (CACE) methods, extended to the analysis of survival data. CACE methods are based on two key assumptions: (i) random allocation ensures that, on average, there are an equal number of non-compliers in each study arm; (ii) the effect of the most conservative treatment is the same irrespective of whether the patient was allocated to that treatment or opted for it after being allocated to a more radical alternative. We will employ the C-PROPHET implementation of this approach (Loeys T, Goetghebeur E. A causal proportional hazards estimator for the effect of treatment actually received in a randomized trial with all-or-nothing compliance. *Biometrics* 2003;59:100-5). This method requires that patients allocated to the more conservative treatment cannot then undergo the more radical alternative. Hence in this secondary analysis we will make the two comparisons between active monitoring and each of surgery and radiotherapy in turn, and we will make the simplifying assumption that patients moving from active monitoring to radical treatment are doing so as part of the active monitoring protocol (i.e. these patients are not swapping between treatment arms, but are moving along the active monitoring treatment pathway). These analyses will be adjusted for the four minimisation variables, as done for the primary analysis.

Secondary analyses will also explore the impact of inaccurate clinical staging prior to treatment, for (effectively) observational studies comparing the treatment options. Clinical staging is acknowledged to be inaccurate, with approximately 25-30% of cases found not to be localised to the prostate when full operative staging is carried out. We will thus have the most accurate (pathological) staging only in one treatment arm (radical surgery), but it is likely that similar levels of upstaging will be occurring in the other arms.

Further secondary analyses will compare estimates using data from the cohort of men who refused random allocation and chose their treatment (the preference cohort) to the estimates from the primary analyses of the randomised trial.

#### *Extended follow-up from 2018 to June 2021*

The statistical methods and analysis for the primary analyses were described in the published version of the protocol and Statistical Analysis Plan, published on <http://hdl.handle.net/1983/14265b05-5d00-40b2-90c7-020db8ee725a>. Analyses for the median 15 year analyses are detailed below and were reviewed by the NIHR HTA in the extension funding application.

#### **Description of Statistical Methods (2018 to June 2021)**

The statistical analysis of primary<sup>3</sup> and secondary<sup>4</sup> outcomes conducted for the median 10-year follow-up will be repeated for the median 15-year follow-up. In brief, the primary outcome of deaths due to prostate cancer or its treatment will be compared among the three assigned treatment groups on an intention-to-treat basis with the use of Cox proportional hazards regression adjusted for trial centre, age at baseline, Gleason score, and PSA level at baseline (log-transformed). The results of a cumulative incidence approach, which will avoid bias due to other causes of death, will also be presented (although there was no evidence of such bias in the primary 10-year analysis). This approach will be adapted as necessary for secondary event-based outcomes, e.g. date of disease progression, date of diagnosis of metastatic disease, and all-cause mortality. The previously specified sub-group analyses will be conducted, investigating whether the relative treatment effects vary by age, clinical stage, Gleason score, and PSA level at diagnosis. Patient reported outcomes completed during the complete 11-year follow-up will be compared among the three assigned treatment groups on an intention-to-treat basis. Two-level random-effects models will be used to accommodate the correlation between the repeated assessments for each man. Two-level linear models will be used for continuous measures, and two-level logistic models were used for binary measures. All models will include trial centre, age at baseline, Gleason score, and PSA level at baseline (log-transformed) as covariates. All men with at least one post-randomisation measure available will be included in an analysis; there are no plans to impute missing assessments, although the possible effect of these on the observed results will be investigated through sensitivity analyses.

#### **The Number of Participants**

The original sample size calculation was presented in published protocol. The ProtecT study randomly allocated 545 men to active monitoring, 553 men to surgery, and 545 men to radiotherapy. Amongst these men, at median 10-year follow-up, there were 8, 5 and 4 prostate cancer deaths respectively. There were very few withdrawals at the time of the median 10-year analyses in randomised men<sup>3</sup>. A simple extrapolation from the occurrence of prostate cancer deaths during the median 10-year follow-up, suggests that by the end of 2020 the number will have doubled from 17 to 34 among those randomised. If there is an increase in the incidence rate of prostate cancer death, as may result from the number of metastatic disease cases that have been diagnosed, then conditional power of 67%, 78%, and 85%, would result from the occurrence of 48, 60, and 72 prostate cancer deaths respectively.

A formal sample size calculation was not undertaken for men in other groups (advanced cancer, comorbidities or with and initial PSA of 20ng/ml or above). All men in these groups will be followed up observationally.

#### **Analysis of Outcome Measures**

The analyses will be conducted as described above.

### **APPENDIX 3: PROGRESSION OF PARTICIPANTS THROUGH PROTECT STUDY**

*Completed in 2009*

Note: X is an exit point, participant does not continue in the ProtecT study.

#### **Participant states pre-PCC**

Returns invitation letter or telephones

1. Yes
2. No = X
3. Refuses = X

PCC list of appointments

1. Attends
2. Did not attend, rebook and then put as refusal after 2 times = X
3. Refuses = X

#### **States at end of PCC clinic**

1. Refuse Consent form 1 points 1-4 = X and blood destroy if PSA done, once men have result
2. Refuse Consent 1 blood tests = X and blood destroy if PSA taken done, once men have result
3. Refuse Consent 1 points 2 /3, continue in ProtecT, but flag not use blood for other studies
4. Ineligibility = X and blood destroy if PSA taken once men have result
5. Eligible and consent 1 obtained for ProtecT and ProMPT for consent 2

#### **States after return of Consent form 3**

1. Refuses consent = X
2. Consent given for PSA test
3. Exit ProtecT study as negative PSA = X
4. Eligible for diagnostic phase as raised PSA

NB 1-3 return all participants' questionnaires and schedules to Bristol inside PCC Schedule

#### **States after diagnostic phase**

1. Localised prostate cancer, PSA 3-19ng/ml and fit to continue
2. Participant refusal to attend biopsy appointment, rebook 2x, if no = X
3. Advanced cancer = X
4. HGPIN alone on biopsy = X
5. Biopsy negative, no HGPIN, PSA free/total <0.12, 2<sup>nd</sup> biopsy = clinical and patient decision

NB: Some of these men will have prostate cancer on subsequent biopsies. The decision to offer more biopsies will depend on repeat PSA, and at the discretion of the clinician with a fully informed patient. If they have localised prostate cancer later, they can be included in ProtecT.

6. Biopsy negative, no HGPIN, PSA free/total  $\geq 0.12$  = X
7. PSA 10-20ng/ml, bone scan, metastases = X
8. PSA 10-20ng/ml, bone scan, localised
9. Ill-health exclusion = X
10. Other exclusion = X

NB 2-10 return all participants' questionnaires and schedules to Bristol inside PCC Schedule

#### **States after Information appointment**

1. Randomised to three arm
2. Randomised to three arm, refuses and expresses preference
3. Selection option, no randomisation
4. No decision, further appointment(s) arranged
5. Withdrawn = X

NB 1-5 return all participants' questionnaires and schedules to Bristol inside PCC Schedule.

## APPENDIX 4: AMENDMENT HISTORY

Version 3.0 and a list of changes made from prior versions are available online in supplementary material (pdf pages 85-86) to the NEJM clinical outcomes paper  
<http://www.nejm.org/action/showSupplements?doi=10.1056%2FNEJMo1606220&viewType=Popup&viewClass=Suppl>

Amendment No.	Protocol Version No.	Date issued	Author(s) of changes	Details of Changes made
	3.0	21/10/2012	JA Lane	See above
	2.4	01/07/2009	JA Lane	See above
	2.3	20/06/2007	JA Lane	See above
	2.2	01/06/2005	JA Lane	See above
	2.1	01/06/2003	JA Lane	See above
	2.0	01/12/2002	JA Lane	See above
	1.0	01/09/2001	JA Lane	See above